The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2

Rahul K. Suryawanshi[1,*], Priyadarshini Jaishankar[2,*], Galen J. Correy[3,*], Moira M. Rachman[2,*], Patrick C. O'Leary[4,*], Taha Y. Taha[1,5,*], Francisco J. Zapatero-Belinchón[1], Maria McCavitt-Malvido[1], Yagmur U. Doruk[4], Maisie G. V. Stevens[4], Morgan E. Diolaiti[4], Manasi P. Jogalekar[4], Alicia L. Richards[5,6,7], Mauricio Montano[1], Julia Rosecrans[1], Michael Matthay[8], Takaya Togo[2], Ryan L. Gonciarz[2], Saumya Gopalkrishnan[5], R. Jeffrey Neitz[2,9], Nevan J. Krogan[3,5,7], Danielle L. Swaney[5,6,7], Brian K. Shoichet[2], Melanie Ott[1,8,10,#], Adam R. Renslo[2,#], Alan Ashworth[4,#], James S. Fraser[3,#]

[1] Gladstone Institute of Virology, Gladstone Institutes, San Francisco, CA
[2] Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA
[3] Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA
[4] Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA
[5] Quantitative Biosciences Institute (QBI), University of California San Francisco, San Francisco, CA
[6] Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA
[7] Data Science and Biotechnology Institute, Gladstone Institutes, San Francisco, CA
[8] Department of Medicine, University of California San Francisco, San Francisco, CA
[9] Small Molecule Discovery Center, University of California San Francisco, San Francisco, CA
[10] Chan Zuckerberg Biohub- San Francisco, San Francisco, CA
[*] These authors contributed equally
[#] Corresponding authors (melanie.ott@gladstone.ucsf.edu, adam.renslo@ucsf.edu, alan.ashworth@ucsf.edu, jfraser@fraserlab.com)

Abstract

SARS-CoV-2 continues to pose a threat to public health. Current therapeutics remain limited to direct acting antivirals that lack distinct mechanisms of action and are already showing signs of viral resistance. The virus encodes an ADP-ribosylhydrolase macrodomain (Mac1) that plays an important role in the coronaviral lifecycle by suppressing host innate immune responses. Genetic inactivation of Mac1 abrogates viral replication *in vivo* by potentiating host innate immune responses. However, it is unknown whether this can be achieved by pharmacologic inhibition and can therefore be exploited therapeutically. Here we report a potent and selective lead small molecule, AVI-4206, that is effective in an *in vivo* model of SARS-CoV-2 infection. Cellular models indicate that AVI-4206 has high target engagement and can weakly inhibit viral replication in a gamma interferon- and Mac1 catalytic activity-dependent manner; a stronger antiviral effect for AVI-4206 is observed in human airway organoids. In an animal model of severe SARS-CoV-2 infection, AVI-4206 reduces viral replication, potentiates innate immune responses, and leads to a survival benefit. Our results provide pharmacological proof of concept that Mac1 is a valid therapeutic target via a novel immune-restoring mechanism that could potentially synergize with existing therapies targeting distinct, essential aspects of the coronaviral life cycle. This approach could be more widely used to target other viral macrodomains to develop antiviral therapeutics beyond COVID-19.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a major threat to public health. Despite the approval of several biologic and small molecule therapeutics, there is an urgent need for new small molecule antivirals with distinct mechanisms of action to overcome potential resistance to existing agents (Li et al. 2023b; von Delft et al. 2023). While most antivirals target an essential aspect of viral entry or replication, a potential avenue for new antivirals with alternative mechanisms is to target viral proteins that act to blunt the host immune response (Minkoff and tenOever 2023). For example, SARS-CoV-2 has evolved multiple mechanisms to evade and counter interferon signaling (Kim and Shin 2021). The viral proteins involved in such evasion would be valuable drug targets if their inhibition renders the host immune response sufficient to control virus replication and reduce disease severity.

The macrodomain (Mac1) of non-structural protein 3 (NSP3) in SARS-CoV-2 is one such target that plays an antagonistic role to the host interferon response (Schuller et al. 2023). Macrodomains are found across the tree of life and catalyze the hydrolysis of ADP-ribose covalent modifications on protein side chains (Dasovich and Leung 2023). Viral macrodomains are found in alphaviruses, hepatitis E virus, and many betacoronaviruses (Leung et al. 2022) and in some systems, like murine hepatitis virus (MHV), their activity can be essential for viral replication (Voth et al. 2021). While SARS-CoV-2 bearing either catalytically inactivating point mutations (Taha et al. 2023b) or deletion of the Mac1 domain (Alhammad et al. 2023) have minor phenotypes in cell culture, their replication is profoundly attenuated in animal models. This discordance likely reflects the inability of cellular models to recapitulate the complex intercellular and systemic signaling required for proper viral-host immune interactions. The underlying mechanism of action results from the enzymatic activity of Mac1, which counters the wave of ADP-ribosylation that is catalyzed by poly-adenosine diphosphate-ribose polymerase (PARP) proteins during the interferon response (Kerr et al. 2023; Kar et al. 2024; Parthasarathy et al. 2024). While the critical proteins and sites modified by interferon-induced PARPs are not fully characterized, the inhibition of Mac1 should allow ADP-ribosylation and the resulting downstream signaling to persist (Kar et al. 2024). Indeed, multiple interferon genes are down-regulated upon infection with wild-type SARS-CoV-2 relative to a Mac1 deficient mutant, consistent with the hypothesis that antiviral interferon signaling could be productively enhanced by Mac1 inhibition (Alhammad et al. 2023; Taha et al. 2023b).

We (Schuller et al. 2021; Gahbauer et al. 2023), and others (O'Connor et al. 2023; Schuller et al. 2023; Wazir et al. 2024), have previously developed inhibitors of Mac1 with activity *in vitro*. However, the therapeutic hypothesis that pharmacological Mac1 inhibition would restore host immune responses and lead to a survival benefit after SARS-CoV-2 infection has not yet been tested. Here, we build on our experimental fragment (Schuller et al. 2021) and virtual screening approach (Gahbauer et al. 2023) with medicinal chemistry, to develop a potent lead compound, AVI-4206, that engages Mac1 in cellular models and has suitable pharmacological properties to test antiviral efficacy *in vivo*. In an animal model of SARS-CoV-2 infection, AVI-4206 reduces viral replication, restores an interferon response, and leads to a survival benefit. Therefore, our results validate Mac1 as a therapeutic target via a novel immune-restoring mechanism that could synergize with existing therapies targeting essential aspects of viral replication. The approach could be more widely used to target other macrodomains in viruses beyond SARS-CoV-2.

Results

Optimization of *in vitro* potency against the SARS-CoV-2 Macrodomain

Previously, we described two novel Mac1 inhibitors, AVI-92 and AVI-219 (Gahbauer et al. 2023), which evolved from fragment screening and virtual screening hits, respectively.heir potency was determined using an ADPr-conjugated peptide displacement-based homogeneous time resolved fluorescence (HTRF) assay (**Figure 1**). The superposition of the Mac1 crystal structures in complex with both leads inspired a parallel approach to optimization, which was supported by additional high resolution X-ray structures of the complexes (**Figure 1**A,E, **Supplementary Table 1**, **Supplementary Figure 1**). First, we generated a merged compound

that used the urea function of AVI-92 in the more lead-like AVI-219 scaffold, thus avoiding the phenolic and carboxylate functionalities present in AVI-92. Indeed, the X-ray structure of the resulting complex between Mac1 and AVI-4051 shows that it preserves and favorably orients the two hydrogen bonding contacts with the carboxylate of Asp22 and exhibits a ~four-fold lower IC_{50} value as compared to AVI-219 in the HTRF assay (**Figure 1**B,E). Further structure activity relationship (SAR) studies revealed a strong preference for urea (e.g., AVI-1500, IC_{50} of ~120 nM) over acetamide (AVI-1501) or carbamate (AVI-3367) in productively engaging Asp22 (**Figure 1**B,E).

Second, at the other end of the adenosine site, we observed that the pyrrolidinone carbonyl of AVI-219 could accept hydrogen bonds from the backbone amides of Phe156/Asp157 (**Figure 1**C,E). To improve contacts with non-polar residues in this sub-site, we next explored substitutions of the pyrrolidinone ring. While C-5 substituents as large as phenyl were tolerated (AVI-3762 and AVI-3763), these analogs showed reduced ligand efficiency compared to AVI-219. By contrast, a methyl group at C-5 in either stereochemical configuration (AVI-3764 and AVI-3765) improved potency and ligand efficiency. Introducing two methyl groups at C-5 afforded the achiral, gem-dimethyl pyrrolidinone AVI-4636 with an impressive five-fold improvement in potency (IC_{50} of ~200 nM) compared to AVI-219 (**Figure 1**C,E).

Ultimately, combining the ethyl urea side chain of AVI-1500 with the gem-dimethyl pyrrolidinone of AVI-4636 produced AVI-4206, the most potent Mac1 inhibitor identified from this series, with an IC_{50} value of ~20 nM (**Figure 1**A,E). This potency approaches the floor of our HTRF assay, which uses 12 nM of enzyme, and indicates that AVI-4206 is at least ~25-100-fold more potent than the AVI-92 and AVI-219 starting points, respectively. The high resolution co-crystal structure of AVI-4206 confirmed that the desired interaction elements and conformations were maintained from the separate optimization paths (**Figure 1**e). To confirm that the high affinity binding of AVI-4206 was reflected in inhibition of Mac1 catalytic activity, we used auto ADP-ribosylated PARP10 and a coupled NudT5/AMP-Glo assay to measure ADP-ribose released by the enzymatic reaction (Kasson et al. 2021) (**Supplementary Figure 2**). This assay demonstrated AVI-4206 potently inhibits Mac1 with an IC_{50} of 64 nM (**Figure 1**D).



Figure 1: **Iterative structure-based design and optimization of AVI-4206 activity against Mac1.**
(A) Evolution of the early lead AVI-219 to AVI-4206 by introducing and optimizing urea functionality as found in AVI-92 to contact Asp22 and introducing geminal dimethyl substitution of the pyrrolidinone ring. HTRF-based IC_{50} values from (B) and (C), and PDB codes from (E) are indicated.
(B and C) HTRF-based dose response curves showing peptide displacement of an ADPr-conjugated peptide from Mac1 by compounds from the urea (B) and the pyrrolidinone ring (C) optimization paths. Data is plotted as % competition mean ± SD of three technical replicates. Data were fitted with a sigmoidal dose-response equation using non-linear regression and the IC_{50} values are quoted with 95% confidence intervals.
(D) Mac1 catalytic activity dose response curve for indicated compounds. Data is plotted as % inhibition mean ± SD of four technical replicates. IC_{50} values are quoted with 95% confidence intervals.
(E) X-ray structures indicating conserved interactions during the optimization path from AVI-92 and AVI-219 (left) to AVI-4206 (right). Structures of compounds from the urea and the pyrrolidinone ring optimization paths are presented in the top and bottom middle panels, respectively. Multiple ligand conformations were observed for AVI-3367, AVI-3762 and AVI-4636 (labeled A and B). The F_O-F_C difference electron density map calculated prior to ligand modeling is shown for AVI-4206 (purple mesh contoured at 5 σ). Electron density maps used to model ligand other ligands are shown in **Supplementary Figure 1**.

AVI-4206 engages Mac1 in cells with high specificity

Having discovered AVI-4206 as a potent inhibitor of Mac1, we next determined whether this compound could enter cells and bind to Mac1 in this context. Therefore, to assess cellular target engagement, we developed a nanoluciferase-based CEllular Thermal Shift Assay (CETSA-nLuc) assay (Martinez et al. 2018) to measure thermal stabilization of Mac1 upon compound binding. A549 cells transiently expressing a HiBiT- and FLAG-tagged Mac1 protein were treated with compounds for 1 hour and then incubated across a gradient of temperatures. After heat exposure, cells were lysed and incubated with LgBiT protein which binds to soluble HiBiT-Mac1 protein reconstituting nanoluciferase and producing a luminescent signal. We observed that the T_{agg} (the temperature at which 50% of protein is soluble) shift for compounds at 10 μM mirrored the affinities measured by the HTRF assay, suggesting a dominant role for Mac1 affinity, rather than bioavailability, or another factor, in determining target engagement in cells (**Figure 2**A). Furthermore, we observed a dose-dependent shift in T_{agg} by AVI-4206, with a marked ~10°C shift in cells treated with 10 μM of compound compared to DMSO-treated control cells (**Figure 2**B). The observations were also validated by western blotting with a FLAG-specific antibody (**Supplementary Figure 3**).

After confirming Mac1 target engagement in cells, we next tested the selectivity of AVI-4206 for Mac1 over two human macrodomains, Targ1 and MacroD2. In an adapted HTRF assay, both human proteins bind to ADP-ribose in the same low-μM range as Mac1 (**Figure 2**C), AVI-4206 does not bind appreciably to either protein in this assay (**Figure 2**D). The selectivity of AVI-4206 for the active site of Mac1 can be rationalized by the presence of larger residues at key positions in the binding pocket in the human orthologs. In Targ1, Cys104 occupies the analogous position to Ala52 of Mac1, leading to a putative clash with the urea moiety (**Figure 2**E). Similarly, in MacroD2, Arg122 occupies the analogous position to Leu 126; both the larger arginine side chain and accompanying backbone shift are predicted to clash with the gem-dimethyl of AVI-4206 (**Figure 2**E). Due to the shared adenosine motif in the substrates for macrodomains and kinases, and the therapeutic importance of protein kinases, we assessed AVI-4206 at 10 μM against a panel of diverse kinases and found no inhibition >35% (**Supplementary Table 2**). Lastly, we used mass spectrometry-based thermal proteome profiling (TPP) (Savitski et al. 2014) to evaluate the selectivity of AVI-4206 against a complex proteome We added 50 nM recombinant Mac1 protein into cellular lysates from A549 cells that were treated either with DMSO or with 100 μM of AVI-4206. We find that Mac1, but no native protein from the A459 lysate, displays a statistically significant shift in melting temperature (3.02°C, adjusted *P* value = 0.045) (**Supplementary Figure 4**). Collectively, these results indicate that AVI-4206 can cross cellular membranes and engage with high specificity for Mac1.



Figure 2: **AVI-4206 engages Mac1 with high potency and selectivity in cells.**
(A) CETSA-nLuc shows differential Mac1 stabilization after treatment of A549 cells with 10 µM of indicated compounds. Data are presented as mean ± SD of two technical replicates. Data were fitted with a sigmoidal dose-response equation using non-linear regression (gray line) and the T_{agg} values are quoted with 95% confidence intervals.
(B) CETSA-nLuc shows a dose-dependent thermal stabilization of Mac1 after treatment of A549 cells with increasing concentrations of AVI-4206. Data are presented as mean ± SD of two technical replicates.
(C and D) HTRF-based dose response curves showing displacement of an ADPr-conjugated peptide from indicated proteins by ADP-ribose (C) or AVI-4206 (D). ADP-ribose was used as a positive control. Data are presented as mean ± SD of three technical replicates. IC_{50} values are quoted with 95% confidence intervals.
(E) Structural modeling of MacroD2 (top, PDB code 4IQY) and Targ1 (bottom, PDB code 4J5S) showing design elements that prevent AVI-4206 cross reactivity. The atoms of clashing residues (Cys140 in MacroD2, Arg122 in Targ1) are shown with a dot representation. The ADP-ribose present in both human macrodomain structures has been omitted for clarity.

AVI-4206 displays limited efficacy in cellular models

To determine whether AVI-4206 can inhibit viral replication in cellular models of SARS-CoV-2 infection, we treated IFN-deficient Vero cells stably expressing TMPRSS2 (Vero-TMPRSS2) and IFN-competent A549 cells stably expressing high levels of ACE2 (A549-ACE2^h) with AVI-4206 and infected them with an mNeon reporter SARS-CoV-2 WA1 strain (Xie et al. 2020). We observed that treatment with AVI-4206 did not reduce viral replication in Vero-TMPRSS2 or A549-ACE2^h cells (**Figure 3**A,B), consistent with previous studies showing that Mac1 deficient SARS-CoV-2 can replicate efficiently in several cell lines ((Alhammad et al. 2023; Taha et al. 2023b)). This result stands in contrast to a SARS-CoV-2 protease inhibitor, nirmaltrevir, which potently inhibited replication in both cell lines (EC_{50} 275 nM and 9.4 nM, respectively) (**Figure 3**A,B). Nonetheless, this experiment, together with a viability assay, indicated no direct cytotoxicity of AVI-4206 at concentrations as high as 100 µM (**Supplementary Figure 5**A,B). Next, we explored whether interferon pre-treatment could potentiate the response of AVI-4206 using SARS-CoV-2 replicons (Taha et al. 2023a) as we previously demonstrated for a Mac1 deficient SARS-CoV-2 replicon (WA1 N40D mutant) (Alhammad et al. 2023; Taha et al. 2023b) (**Figure 3**C). We did not observe a reduction in viral RNA replication of the Mac1 deficient replicon compared with the wild-type replicon in Vero cells stably expressing ACE2 and TMPRSS2 (VAT) or A549-ACE2^h cells treated with or without AVI-4206 and 1000 IU/ml of IFN-gamma (**Supplementary Figure 5**C,D). However, there was a modest dose-dependent decrease in replication of the wild-type, but not Mac1 deficient, replicon in A549-ACE2^h cells (**Supplementary Figure 5**D). When the IFN-gamma dose was increased to 10000 IU/ml, we observed a small (~1.6-fold) effect for the Mac1 deficient

replicon relative to the wild-type replicon (**Figure 3**D). Treatment with highest dose (100 μM) of AVI-4206 led to a statistically significant, but small (~1.7-fold), reduction in replication for the wild-type, but not Mac1-deficient, replicon (**Figure 3**D). From these experiments, we conclude that cellular models of SARS-CoV-2 infection give, at best, only a narrow window for assessing the efficacy of Mac1 inhibition and that high concentrations of AVI-4206 can achieve a limited anti-viral response without cytotoxicity in an IFN- and Mac1 catalytic activity-dependent manner.

To test AVI-4206 in a system that more closely replicates both the structural and functional characteristics of the human airway epithelium, we used human airway organoids (HAOs), which are derived from primary stem cells generated from human lungs and grow as complex three-dimensional structures (Sachs et al. 2019). These cells can be differentiated into the various cell types found in the airway epithelium, including ciliated, goblet, and basal cells (Li et al. 2023a; Simoneau et al. 2024). We (Simoneau et al. 2024) and others (Li et al. 2023a) have utilized differentiated HAOs as a more relevant infection model that encompasses more robust innate immune functions. We therefore sought to test the efficacy of AVI-4206 in HAOs infected with SARS-CoV-2 (**Figure 3**E). The Mac1 deficient virus (WA1 N40D mutant) showed no reduction, 10-fold reduction, and 1000-fold reduction in viral particle production at 24, 48, and 72 hours post-infection compared to the wild-type virus (**Figure 3**F). AVI-4206 treatment reduced viral particle production 10- and 100-fold at 48 and 72 hours post-infection, respectively, and 20 μM AVI-4206 reduced viral particle production by 10-fold at 72 hours post-infection (**Figure 3**F). As we have observed previously (Alhammad et al. 2023; Taha et al. 2023b), the faster clearance of infection in AVI-4206 treated HAOs, similar to that seen with the Mac1 deficient virus, is likely due to a potent innate immune response rather than a direct effect of Mac1 on viral replication. While these cellular and organoid experiments gave some indication of an effect of AVI-4206, testing in animal models was required to establish whether this compound had significant activity in reducing viral pathogenesis.



Figure 3: AVI-4206 shows limited efficacy in cellular models of SARS-CoV-2 infection.
(A and B) Vero-TMPRSS2 (A) or A549-ACE2^h (B) cells were pretreated with compounds and infected with mNeonGreen reporter SARS-CoV-2. mNeonGreen expression was measured by the Incucyte system. Graphs represent mean +/- SD of % replication normalized to the DMSO control 24 post-infection of three independent experiments performed in triplicate. Data were fitted with a sigmoidal dose-response equation using non-linear regression (gray line) and the EC_{50} values are quoted with 95% confidence intervals.
(C) Schematic of the replicon assay to test the efficacy of AVI-4206 in A549 ACE2^h cells.
(D) Luciferase readout of A549 ACE2^h cells infected with WA1 or WA1 Mac1 N40D replicons and treated with or without AVI-4206 and IFN-ɣ at indicated concentrations; *, $P < 0.05$ by two-tailed Student's t-test relative to the no AVI-4206 and no IFN-ɣ control. Results are plotted as normalized mean ± standard deviation luciferase values of a representative biological experiment containing two technical replicates.
(E) Schematic of the HAO experiment.
(F) Viral particle production was measured by plaque assay at indicated time points and AVI-4206 concentrations. Error bars indicate s.e.m. **, $P < 0.01$; *, $P < 0.05$ by two-tailed Student's t-test relative to the vehicle control.

AVI-4206 has favorable pharmacological properties

Prior to testing the efficacy of AVI-4206 in animal models, we assessed the pharmacological properties of the compound to predict a dosing regime that would provide sufficient target coverage to test efficacy. In parallel with optimizing compounds for potent inhibition of Mac1, as described above, we employed data from standard *in vitro* assays of metabolism, permeability, and physicochemical properties to drive our medicinal chemistry campaign. Thus, the series leading to AVI-4206 was optimized for stability in mouse liver microsomes and human hepatocytes, low plasma protein binding (good free fraction), and high aqueous solubility (**Figure 4**A). However, the introduction of the urea functionality in this series negatively impacted permeability in Caco-2 monolayers when compared to the parent AVI-219, predicting low oral bioavailability. Indeed, in mouse pharmacokinetic (PK) studies, AVI-4206 showed poor oral bioavailability (<4%), while intrinsic clearance was moderate, about 60% of hepatic blood flow (**Supplementary Table 3**). Bioavailability via the intraperitoneal (IP) route however, was excellent and free drug concentrations ~100-fold above the biochemical IC_{50} were achieved for 8 hours following a single IP dose at 100 mg/kg (**Figure 4**B, **Supplementary Table 3**). In a separate PK experiment employing a 10 mg/kg IP dose, total exposure of AVI-4206 in lung was higher than in plasma at later time points, (**Figure 4**C), suggesting its suitability for an *in vivo* infection model to validate Mac1 as an antiviral target Moreover, AVI-4206 showed minimal inhibition of common cytochrome P450 (CYP) isoforms (**Figure 4**D) and a broader panel of potential off targets (**Figure 4**E, **Supplementary Table 4**), identified no significant liabilities among major channels, receptors, or enzymes. Overall, the biochemical potency and PK profile of AVI-4206 suggested the likelihood of sustained target engagement in mice with twice daily doses (BID) of 100 mg/kg by the IP route allowing us to test proof-of-concept.



Figure 4: AVI-4206 has a favorable pharmacological profile.
(A) Pharmacokinetic properties of AVI-4206.
(B) Unbound plasma exposure time course of AVI-4206, corrected for plasma protein binding, following administration by IV, PO, or IP routes in male CD-1 mice at the indicated doses.
(C) Free plasma exposure of AVI-4206 and total exposure in lung homogenate following an IP dose of 10 mg/kg in female C57BL/6 mice.
(D) Inhibition of CYP isoforms by AVI-4206 at a fixed concentration of 10 µM. Two experiments were performed with CYP3A4 using different positive controls.
(E) Heatmap of AVI-4206 activity in an off-target safety panel including receptors, ion channels, and proteases, showing no antagonist response >15% at 10 µM.

AVI-4206 is effective in a mouse model of SARS-CoV-2 infection

To assess the efficacy of AVI-4206 *in vivo*, we used the K18-hACE2 mouse model, which mimics severe SARS-CoV-2 infection (Zheng et al. 2021). The K18-hACE2 mouse is a stringent model to test efficacy, as previous studies using potent protease inhibitors did not lead to full survival, unless combined with molnupiravir (Papini et al. 2024). In our experiment, animals were divided into three groups (wild-type WA1

virus with compound or vehicle treatment, and a Mac1 deficient mutant-infected positive control) with treatment (AVI-4206 at 100 mg/kg intraperitoneally, nirmatrelvir at 300 mg/kg orally, or vehicle control for each drug) initiated one day prior to infection (**Figure 5**A). AVI-4206 or nirmatrelvir were administered twice daily until 5 days post-infection, during which the mice were closely monitored for disease parameters such as weight loss and hunched posture. Both vehicle-treated groups experienced weight loss starting at 3-4 days post-infection and continued losing weight until the end of the study at 7 days post-infection (**Figure 5**B,C). The AVI-4206 and nirmatrelvir treated groups experienced weight loss starting at 4 days post-infection, but the extent of weight loss was about 5-10% lower on average at days 5-7 post-infection compared with their respective vehicle-treated groups (**Figure 5**B,C). Consequently, ~70% of AVI-4206 treated group and 40% of the nirmatrelvir treated group survived, whereas all mice in the vehicle treated groups died by the end of the study based on the humane endpoints of hunched posture or >20% decrease in body weight (**Figure 5**D,E). Consistent with previous studies (Taha et al. 2023b), none of the mice in the mutant-infected positive control group experienced weight loss, and all survived the infection (**Figure 5**D). These results indicate that AVI-4206 can significantly reduce disease severity and prevent death in the K18-hACE2 model and is comparable to the FDA-approved protease inhibitor nirmatrelvir.

To understand the mechanism of AVI-4206 action during the course of infection, mice from each group were euthanized at either day 4 or 7. We observed that AVI-4206 treatment reduced viral load in the lungs by ~10-fold and ~100-fold at 4 and 7 days post-infection, respectively, and reduced transmission to the brain (**Figure 5**F). Although it is possible that AVI-4206 crosses the blood-brain barrier, it is more likely that the reduction of viral load in the brain is as a consequence of a reduction in overall systemic viral load. The prevention of virus localization to the brain is especially important in this model because human ACE2 overexpression allows virus replication and spread to brain tissue which ultimately leads to encephalitis and the death of infected mice (Bao et al. 2020; Oladunni et al. 2020). The faster clearance of viral load in the lungs for AVI-4206 treated and Mac1 deficient virus infected mice compared with the vehicle-treated mice, rather than an early antiviral effect post-infection, is consistent with an immune response mediated mechanism rather than a direct antiviral mechanism.

To further investigate the antiviral mechanism of AVI-4206, we measured the abundance of the antiviral cytokines IP-10, IL-2, IL-6, and TNF-α in lung tissue at 4 and 7 days post-infection (**Figure 5**G). We found that levels of all of these cytokines were elevated at 4 days post-infection. At 7 days post-infection, the AVI-4206 treated and Mac1 deficient virus infected mice maintained significantly higher levels of IP-10, IL-2, and IL-6 ($P < 0.05$) compared to the vehicle treated group; TNF-α showed a similar trend but did not reach statistical significance (**Figure 5**G). The lower levels of cytokines in the vehicle-treated group at 7 days post-infection is likely mediated by the immune-suppressive capability of SARS-CoV-2 macrodomain. However, when the macrodomain is inactivated, either through AVI-4206 treatment or infection with Mac-1 defective variant, the antiviral response is enhanced, which blocks viral replication. The cumulative cytokine abundance (IP-10, IL-2, and IL-6) indicates an antiviral immune response, likely mediated through the activation of the NF-κB pathway (Neufeldt et al. 2022; Robertson et al. 2023). Finally, we tested the efficacy of AVI-4206 at a lower dosage of 30 mg/kg using the same experimental setup. Even at this lower dose, AVI-4206 enhanced survival and produced lower viral load at 7 days post-infection relative to vehicle (**Supplementary Figure 6**), but to a more modest degree than at the higher dose (**Figure 5**). Collectively, our observations of enhanced survival of mice, reduced viral load, and an increase in antiviral cytokines suggest that AVI-4206 is capable of potentiating the host immune response, thereby reducing disease severity.



Figure 5: **AVI-4206 reduces viral replication and increases survival and cytokine abundance *in vivo***.
(A) K18-hACE2 mice were intranasally infected and dosed as indicated with either AVI-4206 (n=15, intraperitoneally), nirmatrelvir (n=5, per os) or vehicle (n=10 for the AVI-4206 group or n=5 for the nirmatrelvir group). Mice infected with WA1 N40D mutant, which lacks Mac1 catalytic activity, served as a positive control (n=10). Lungs were harvested at indicated time points for virus titration by plaque assay.
(B) The percent body weight loss for all animals treated with AVI-4206 (100 mg/kg IP) **(C)** or nirmatrelvir (300 mg/kg PO). The data are presented as mean ± SD. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$ by two-tailed Student's t-test relative to the vehicle control at each timepoint.
(D) Survival curve plotted based on the percent weight loss humane endpoint (20%) for AVI-4206 and **(E)** nirmatrelvir.
(F) Viral load in the lungs and brain of infected mice at the indicated time points. The data are shown as mean ± s.e.m. *, $P < 0.05$; **, $P < 0.01$ by Mann Whitney's test relative to the vehicle control.
(G) Schematics and graphs demonstrating the abundance of indicated cytokines at 4 and 7 days post-infection in the lungs of infected mice. The data are presented as mean ± s.e.m. *, $P < 0.05$; **, $P < 0.01$ by two-tailed Student's t-test relative to the vehicle control at each timepoint. None of the mice reached the humane endpoint at day 4 post-infection. For mice that reached the humane endpoint before day 7 post-infection, the tissues were collected and analyzed with mice at the 7 day time point.

Discussion

Here we provide strong pharmacological evidence validating Mac1 and de-ADP-ribosylation as a therapeutic target for SARS-CoV-2. AVI-4206 is a competitive inhibitor that blocks the ADP-ribosylhydrolase activity of Mac1. This activity antagonizes the PARP-mediated ADP-ribosylation that is part of the antiviral interferon

response. Although mechanistic links are still emerging between specific post-translational modifications and an effective antiviral response, our pharmacologic studies add to the genetic and biochemical evidence of the importance of this signaling axis for viral replication *in vivo (*Alhammad et al. 2023; Taha et al. 2023b). Our work also adds to the growing role of modulating ADP-ribosylation signaling in therapeutic development (Dasovich and Leung 2023). For example, inhibitors of PARP1, which catalyzes the addition of poly- ADP-ribose marks, have been developed for treating tumors with mutations in either *BRCA1* or *BRCA2* (Lord and Ashworth 2017) and inhibitors of PARG, which catalyzes the removal of α(1″-2′) O-glycosidic linkages in PAR chains, are under investigation for a variety of cancers (Slade 2020). The presence of macrodomains and experimental evidence for them as interferon signaling antagonists in other diverse viruses, such as Chikungunya (McPherson et al. 2017), suggests that inhibiting this target class may be effective for treatment of other virally-induced diseases beyond COVID.

While AVI-4206 is protective in an animal model of infection, it was developed without many of the normal intermediate markers of improvement in cellular models. This discordance was expected based on the mechanism of action, as interferon-based antiviral activity likely requires intra- and inter-cellular and systemic communication between different cell types (Platanias 2005). The limited replication defect difference between wild-type and Mac1 deficient viruses in cellular models renders them largely ineffective as a model to test the effects of macrodomain inhibition, which has led others to question the validity of Mac1 as target (Lee et al. 2024). AVI-4206 did in fact demonstrate modest antiviral activity only in the presence of exogenous IFN in cells, which is consistent with most other studies that have examined Mac1 activity (Alhammad et al. 2023; Taha et al. 2023b; Kerr et al. 2024). While a larger replication defect is observed in HAOs likely due to their more relevant antiviral innate immune responses (Simoneau et al. 2024), the highest dose of AVI-4206 does not achieve the magnitude of the replication defect of the Mac1 deficient virus. This may reflect an unoptimized prophylactic dosing schedule or the need to better tune the pharmacological properties of the inhibitor. Taken together, the concordance of *in vitro* (HTRF) and cellular target engagement assays (CETSA) stands out as particularly important in the development path of macrodomain inhibitors.

AVI-4206 blocks the viral enzymatic removal of post-translational modifications important for the immune response, which is an important mechanism for blocking virus replication and reducing disease severity. Notably, Mac1 represents a second pharmacologically validated enzymatic domain within Nsp3: a recently developed inhibitor of the papain-like protease (PLpro) domain also shows efficacy in animal models and acts by removing a distinct set of host post-translational modifications (ubiquitin and interferon-stimulated gene 15 (ISG15)) (Tan et al. 2024). In summary, AVI-4206 provides proof-of-concept for the validation of a novel antiviral target, Mac1. By restoring the antiviral immune response, the novel mechanism of action of AVI-4206 could be synergistic or additive with orthogonally acting direct antivirals, such as protease and polymerase inhibitors, in combination therapies for the treatment of SARS-CoV-2 infection and beyond.

Acknowledgments

This work was supported by the National Institutes of Health (NIAID Antiviral Drug Discovery (AViDD) grant U19AI171110. M.O. is supported by the James B. Pendleton Charitable Trust and the Roddenberry Foundation. The synchrotron X-ray diffraction data used to determine Mac1 structures were collected at beamline 8.3.1 of the Advanced Light Source (ALS) and beamlines 9-2, 12-1 and 12-2 of the Stanford Synchrotron Radiation Lightsource (SSRL). The ALS, a U.S. DOE Office of Science User Facility under contract no. DE-AC02-05CH11231, is supported in part by the ALS-ENABLE program funded by the NIH, National Institute of General Medical Sciences, grant P30 GM124169. Use of the SSRL, SLAC National Accelerator Laboratory, is supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences under Contract No. DE-AC02-76SF00515. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research, and by the National Institutes of Health, National Institute of General Medical Sciences (P30GM133894).

Methods

Synthetic Chemistry

General Experimental Procedures:

Unless otherwise noted all chemical reagents and solvents used are commercially available. AVI-92 and AVI-219 were synthesized as previously described (Gahbauer et al. 2023). Reverse phase chromatography was carried out on one of the following instruments: (i) Waters 2535 Separation module with Waters 2998 Photodiode Array Detector. Separations were carried out on XBridge Preparative C18, 19 × 50 mm column at ambient temperature using a mobile phase gradient of water-acetonitrile-0.1% formic acid. (ii) Gilson GX-281 instrument, separations using Xtimate Prep C18, 21.2*250 mm, 150 Å, 10 µm particle size column.(iii) Agilent 1260 Infinity systems equipped with DAD and mass-detector. Separations carried out on Chromatorex 18 SMB100-5T 100x19 mm 5 µm column using mobile phase gradient of water/methanol/0.005% HCl. Chiral separations were carried out on CHIRALPAK IA (250x21 mm, 5 mkm)-II column at ambient temperature using a mobile phase of hexane (0.3% DEA): IPA:MeOH, 90:5:5. LC/MS data were acquired by one of the following instruments: (i) Waters Acquity UPLC QDa mass spectrometer equipped with Quaternary Solvent Manager, Photodiode Array Detector and Evaporative Light Scattering Detector. Separations were carried out with Acquity UPLC BEH C18 1.7 mm, 2.1 × 50 mm column at 25°C, using a mobile phase gradient of water-acetonitrile containing a constant 0.1% formic acid. Detection: UV (254 nm), ELS and MS (ESI, positive mode), (ii) Agilent 1100 Series LC/MSD system with DAD\ELSD Alltech 2000ES and Agilent LC\MSD VL (G1956B), SL (G1956B) mass-spectrometer, (iii) Agilent 1200 Series LC/MSD system with DAD\ELSD Alltech 3300 and Agilent LC\MSD G6130A, G6120B mass-spectrometer, (iv) Agilent Technologies 1260 Infinity LC/MSD system with DAD\ELSD Alltech 3300 and Agilent LC\MSD G6120B mass-spectrometer, or (v) Agilent Technologies 1260 Infinity II LC/MSD system with DAD\ELSD G7102A 1290 Infinity II and Agilent LC\MSD G6120B mass-spectrometer.Separations were carried out with_InfinityLab Poroshell 120 SB-C18 4.6x30 mm 2.7 µm column at 25°C, using a mobile phase gradient of water-acetonitrile containing a constant 0.1% formic acid. Detection using DAD1A 215 nm, DAD1B 254 nm MSD – single quadrupole, AP-ESI (positive/negative mode switching). (vi) Agilent 1200 Infinity LC with an Agilent 1956 single quadrupole MS using electrospray ionization. Separations were carried out on a SunFire C18 (4.6x 50 mm, 3.5 µm) column at 50°C using a mobile phase gradient of water (10 mmol NH_4HCO_3) / acetonitrile. Detection: UV (214, 254 nm) and MS (ESI, POS mode ,103 to 100 atomic mass units). Chemical shifts are reported in units of ppm. NMR spectra were referenced relative to residual NMR solvent peaks. Coupling constants (J) are reported in hertz (Hz). NMR spectra were recorded on one of the following instruments: (i) Bruker AVANCE DRX 500 (500 MHz magnet with 5 mm QNP $^{31}P/^{13}C/^{15}N$ and 5 mm TXI probe), (ii) Agilent ProPulse 600 (600 MHz magnet with 5 mm OneNMR probe) and (iii) Bruker Avance III HD 400 MHz spectrometer.

1-((8-Amino-9H-pyrimido[4,5-b]indol-4-yl)amino)pyrrolidin-2-one



A solution 3-fluoro-2-nitroaniline (11 g, 70.51 mmol) in acetic anhydride (20 ml) was stirred at room temperature for 16 hours. The reaction mixture was filtered and the solids were washed with petroleum ether (100 ml) and dried to obtain 10.7 g (77%) of N-(3-fluoro-2-nitrophenyl)acetamide as a brown solid. LCMS (ESI): m/z= 199.3 $(M+H)^+$

To a solution of N-(3-fluoro-2-nitrophenyl)acetamide (10.7 g, 54.04 mmol) in DMF (100 ml) was added methyl 2-isocyanoacetate (8.02 g, 81.06 mmol) and potassium carbonate (14.92 g, 108.08 mmol). After stirring at 80°C for 2 hours, the reaction mixture was cooled to room temperature, acidified with 2 N HCl (ca. 2000 ml), and extracted with ethyl acetate (300 ml *3). The combined organic layers were washed with brine (100 ml), dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel chromatography (10:1 petroleum ether/ethyl acetate) to obtain 11 g (73%) of methyl 2-(3-acetamido-2-nitrophenyl)-2-isocyanoacetate as a yellow solid. LCMS (ESI): m/z = 278.2 $(M+H)^+$

To a solution of methyl 2-(3-acetamido-2-nitrophenyl)-2-isocyanoacetate (11 g, 39.71 mmol) in *glacial* acetic acid (100 ml), was added slowly zinc dust (25.81 g, 397.10 mmol) in two portions. After stirring at 60°C for 2 h, the reaction mixture was cooled to room temperature, filtered and washed with THF. The filtrate was concentrated under reduced pressure and purified by silica gel chromatography (10:1 dichloromethane/methanol) to obtain 6.2 g (63%) of methyl 7-acetamido-2-amino-1H-indole-3-carboxylate as a yellow solid. LCMS (ESI): m/z = 248.3 $(M+H)^+$

A solution of methyl 7-acetamido-2-amino-1H-indole-3-carboxylate (6.2 g, 25.10 mmol) in formamide (450 ml) was stirred at 220°C for 2 hours. The reaction mixture was then cooled to room temperature and poured in 100 ml of water. The resulting mixture was allowed to stand for 15 min before the solids were collected by filtration, washed with water, and dried to obtain 4.1 g of a 1:2 mixture of N-(4-hydroxy-9H-pyrimido[4,5-b]indol-8-yl)acetamide and N-(4-hydroxy-9H-pyrimido[4,5-b]indol-8-yl)formamide. This mixture was taken in methanol (25 ml) and aqueous 12 N NaOH (25 ml). After stirring at 60°C for 16 h, the reaction mixture was then cooled to room temperature, concentrated under reduced pressure to remove methanol and the residue was poured into 100 ml of water. The resulting mixture was allowed to stand for 15 min before the solids were collected by filtration, washed with water, and dried to obtain 3.5 g (70%) of 8-amino-9H-pyrimido[4,5-b]indol-4-ol as a brown solid. LCMS (ESI): m/z = 201.2 $(M+H)^+$

A solution of 8-amino-9H-pyrimido[4,5-b]indol-4-ol (3.5g, 17.5 mmol) in formamide (30 ml) was stirred at 150°C. After 6 h, the reaction mixture was cooled to room temperature and poured into water (200 ml). The resulting mixture was allowed to stand for 15 min before the solids were collected by filtration, washed with

water, and dried to obtain 3.5 g (88%) of N-(4-hydroxy-9H-pyrimido[4,5-b]indol-8-yl)formamide as a brown solid. LCMS (ESI): m/z = 229.2 $(M+H)^+$

To a solution of N-(4-hydroxy-9H-pyrimido[4,5-b]indol-8-yl)formamide (3.5 g, 15.35 mmol) in phosphorous oxychloride (30 ml) was added N,N-diiisopropylethylamine (5.94 g, 46.05 mmol), After refluxing for 16 hours, the reaction mixture was cooled to room temperature, concentrated and poured into water (20 ml). The resulting solid was filtered to obtain 500 mg of a mixture of N-(4-chloro-9H-pyrimido[4,5-b]indol-8-yl)formamide and 4-chloro-9H-pyrimido[4,5-b]indol-8-amine as a black solid. This mixture was taken in 4 N HCl in dioxane (15 ml). After stirring at room temperature for 4 h, reaction mixture was concentrated under reduced pressure, the residue was adjusted to pH 7 with aqueous Na_2CO_3, and extracted with ethyl acetate (3 × 30 ml). The organic layers was dried over sodium sulfate, concentrated under reduced pressure and the residue was purified by reverse phase chromatography (water/acetonitrile / 0.1% ammonium bicarbonate) to obtain 320 mg (10%) of 4-chloro-9H-pyrimido[4,5-b]indol-8-amine as a white solid. ^{1}H NMR (500 MHz, DMSO) δ 12.42 (s, 1H), 8.74 (s, 1H), 7.58 (d, *J* = 7.8 Hz, 1H), 7.25–7.08 (m, 1H), 6.93 (d, *J* = 7.7 Hz, 1H), 5.76 (s, 2H). LCMS (ESI): m/z = 219.2 $(M+H)^+$

A mixture of 4-chloro-9H-pyrimido[4,5-b]indol-8-amine (28 mg, 0.13 mmol) and 1-aminopyrrolidin-2-one hydrochloride (35 mg, 0.26 mmol) in isopropanol/water (10: 1, 1.1 ml) were heated to 100°C for 18 h. The reaction mixture was filtered, the residue was washed with ethyl acetate and dried to obtain 28 mg (77%) of 1-((8-amino-9H-pyrimido[4,5-b]indol-4-yl)amino)pyrrolidin-2-one as brown solid. ^{1}H NMR (DMSO-d_6, 400 MHz) δ 12.99 (br s, 1H), 8.62 (s, 1H), 7.92 (br d, 1H, *J* = 7.5 Hz), 7.27 (t, 1H, *J* = 7.9 Hz), 7.05 (br d, 1H, *J* = 7.5 Hz), 3.70 (br t, 2H, *J* = 6.9 Hz), 2.44-2.53 (m, 2H), 2.20 (br t, 2H, *J* = 7.4 Hz). ^{13}C NMR (METHANOL-d_4, 100 MHz) δ 175.9, 155.9, 154.3, 153.2, 132.5, 125.7, 121.9, 119.4, 111.3, 111.1, 97.0, 48.6, 47.9, 28.5, 15.9. LCMS (ESI): m/z= 283 $(M+H)^+$

1-Amino-5,5-dimethylpyrrolidin-2-one hydrochloride



To a cooled (0°C) solution of 5,5-dimethylpyrrolidin-2-one (3 g, 26.54 mmol) in THF (60 ml) was added sodium hydride (2.13 g, 53.09 mmol), followed by addition of (aminooxy)diphenylphosphine oxide (12.4 g, 53.09 mmol) after 30 min. After stirring the resultant white suspension at 0C for 2 h, the reaction mixture was filtered through a Celite pad, the filtrate was concentrated and purified by silica gel chromatography (10:1 dichloromethane/methanol) to afford 3 g (75%) of 1-amino-5,5-dimethylpyrrolidin-2-one as yellow oil. LCMS (ESI): m/z= 129.1 $(M+18)^+$;

A solution of 1-amino-5,5-dimethylpyrrolidin-2-one (1.5 g, crude) in 4 N HCl in dioxane (15 ml) was stirred at room temperature for 4h. The mixture was concentrated under reduced pressure, residue was triturated with diethyl ether and filtered to afford 1 g (53%) of 1-amino-5,5-dimethylpyrrolidin-2-one hydrochloride salt as a white solid. 1H NMR (500 MHz, DMSO) δ 9.48 (s, 3H), 2.39 (t, 2H, J = 7.8 Hz), 1.90 (t, 2H, J = 7.8 Hz), 1.30 (s, 6H). LCMS (ESI): m/z= 129.1 $(M+18)^+$

AVI-4051



To a solution of 1-((8-amino-9H-pyrimido[4,5-b]indol-4-yl)amino)pyrrolidin-2-one (20 mg, 0.071 mmol) and triethylamine (0.040 ml, 0.28 mmol) in THF (1 ml), was added cyclopropyl isocyanate (24 mg, 0.28 mmol). After stirring at 65 ºC for 48 h, the reaction mixture was purified by reverse phase chromatography (water/acetonitrile/0.1% formic acid) to obtain 12 mg (41%) of 1-cyclopropyl-3-(4-((2-oxopyrrolidin-1-yl)amino)-9H-pyrimido[4,5-b]indol-8-yl)urea formic acid salt (AVI-4051) as a white solid. ^{1}H NMR (DMSO-d_6, 400 MHz) δ 11.81 (br s, 1H), 9.31 (s, 1H), 8.50 (br s, 1H), 8.41 (s, 1H), 7.99 (d, 1H, *J* = 7.8 Hz), 7.63 (d, 1H, *J* = 7.8 Hz), 7.21 (t, 1H, *J* = 7.9 Hz), 6.74 (br s, 1H), 3.70 (br t, 2H, *J* = 7.1 Hz), 3.12-3.17 (m, 2H), 2.54-2.65 (m, 1H), 2.39-2.43 (m, 2H), 0.98 (t, 2H, *J* = 7.1 Hz), 0.68-0.70 (m, 2H). LCMS (ESI): m/z= 366 $(M+H)^+$

AVI-1501



To a solution of 1-((8-amino-9H-pyrimido[4,5-b]indol-4-yl)amino)pyrrolidin-2-one (15 mg, 0.053 mmol) and triethylamine (0.015 ml, 0.11 mmol) in THF (1 ml), was added acetyl chloride (0.004 ml, 0.056 mmol). After stirring at 65°C for 3 h, the reaction mixture was purified by reverse phase chromatography (water/acetonitrile/0.1% formic acid) to obtain 9 mg (50%) of N-(4-((2-oxopyrrolidin-1-yl)amino)-9H-pyrimido[4,5-b]indol-8-yl)acetamide formic acid (**AVI-1501**) as a white solid. ^{1}H NMR (METHANOL-d_4, 400 MHz) δ 8.39 (s, 1H), 7.90 (d, 1H, *J* = 7.8 Hz), 7.45 (d, 1H, *J* = 7.8 Hz), 7.19-7.21 (m, 1H), 3.81-3.85 (m, 2H), 2.59-2.63 (m, 2H), 2.27-2.31 (m, 5H). LCMS (ESI): m/z= 325 $(M+H)^+$

AVI-3367



To a solution of 1-((8-amino-9H-pyrimido[4,5-b]indol-4-yl)amino)pyrrolidin-2-one (15 mg, 0.053 mmol) and triethylamine (0.015 ml, 0.11 mmol) in THF (1 ml), was added ethyl chloroformate (0.005 ml, 0.056 mmol). After stirring at 65°C for 18 h, the reaction mixture was purified by reverse phase chromatography (water/acetonitrile/0.1% formic acid) to obtain 2.7 mg (13%) of ethyl (4-((2-oxopyrrolidin-1-yl)amino)-9H-

pyrimido[4,5-b]indol-8-yl)carbamate formic acid salt (**AVI-3367**) as tan solid. 1H NMR (METHANOL-d4, 400 MHz) δ 8.42 (s, 1H), 7.94 (d, 1H, J = 7.8 Hz), 7.59 (br s, 1H), 7.28 (t, 1H, J = 7.9 Hz), 4.1-4.26-4.30 (m, 2H), 3.84 (t, 2H, J = 7.1 Hz), 2.60 (t, 2H, J = 8.0 Hz), 2.30-2.33 (m, 2H), 1.36-1.39 (m, 3H). LCMS (ESI): m/z= 355 (M+H)+

AVI-1500



To a solution of 4-chloro-9H-pyrimido[4,5-b]indol-8-amine (50 mg, 0.23 mmol) and triethylamine (0.064 ml, 0.46 mmol) in THF (2 ml), was added ethyl isocyanate (0.018 ml, 0.23 mmol). After stirring at 65°C for 18 h, the reaction mixture was filtered. The residue was washed with ethyl acetate and dried to obtain 50 mg of 1-(4-chloro-9H-pyrimido[4,5-b]indol-8-yl)-3-ethylurea as a white solid that was used without further purification. 1H NMR (DMSO-d_6, 400 MHz) δ 12.39 (br s, 1H), 8.80 (s, 1H), 8.43 (s, 1H), 7.96 (d, 1H, J = 7.6 Hz), 7.72 (d, 1H, J = 7.8 Hz), 7.35 (t, 1H, J = 7.9 Hz), 6.38 (s, 1H), 3.18-3.21 (m, 2H), 1.12 (t, 3H, J = 7.2 Hz). LCMS (ESI): m/z = 290, 292 (M+H)+

A mixture of 1-(4-chloro-9H-pyrimido[4,5-b]indol-8-yl)-3-ethylurea (26 mg, 0.09 mmol) and 1-aminopyrrolidin-2-one hydrochloride (25 mg, 0.18 mmol) in isopropanol/water (10: 1, 1.1 ml) were heated to 100°C for 18 h. The reaction mixture was purified by reverse phase chromatography (water/acetonitrile/0.1% formic acid) to obtain 8 mg (20%) of 1-ethyl-3-(4-((2-oxopyrrolidin-1-yl)amino)-9H-pyrimido[4,5-b]indol-8-yl)urea formic acid salt (**AVI-1500**) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 11.75 (br s, 1H), 9.31 (s, 1H), 8.53 (s, 1H), 8.41 (s, 1H), 7.97 (d, 1H, J = 7.8 Hz), 7.63 (d, 1H, J = 7.8 Hz), 7.20 (t, 2H, J = 7.9 Hz), 6.37 (br s, 1H), 3.70 (t, 2H, J = 7.1 Hz), 3.17-3.20 (m, 2H), 2.39-2.41 (m, 2H), 2.12-2.16 (m, 2H), 1.09-1.13 (m, 3H). ^{13}C NMR (DMSO-d6, 100 MHz) δ 173.5, 156.2, 155.9, 155.5, 155.0, 128.5, 125.5, 121.3, 120.3, 117.1, 116.7, 96.4, 48.4, 34.8, 28.9, 16.7, 15.9. LCMS (ESI): m/z = 354 (M+H)+

AVI-3762 & AVI-3763



4-Chloro-7-fluoro-9H-pyrimido[4,5-b]indole (123 mg, 0.55 mmol) and 1-amino-5-phenyl-pyrrolidin-2-one (117 mg, 0.66 mmol) in a mixture of dioxane*HCl/IPA (1.5 ml/1.5 ml) was stirred at 95°C overnight. Upon completion the mixture was cooled to rt and concentrated under reduced pressure. The crude material was purified by HPLC (30-80% MeOH/H_2O) to afford 1-((7-fluoro-9H-pyrimido[4,5-b]indol-4-yl)amino)-5-phenylpyrrolidin-2-one (69 mg, HCl salt, 34% yield). It was further separated by chiral chromatography (Hexane-IPA-MeOH, 50-25-25) to obtain **AVI-3762** (27 mg, retention time = 14.04 min, 99% optic ee) and **AVI-3763** (26 mg, retention time = 11.17 min, 100% optic ee).

AVI-3762: H1 NMR (500 MHz,DMSO) δ 12.2 (s, 1H), 9.47-9.28 (m, 1H), 8.41 (s, 1H), 8.24 (dd, J = 8.8, 5.5 Hz, 1H), 7.45 (d, J = 7.1 Hz, 1H), 7.32 (t, J = 7.4 Hz, 1H), 7.27-7.18 (m, 1H), 7.14-7 (m, 1H), 5.26-5.07 (m, 1H), 2.57-2.49 (m, 3H), 1.93-1.78 (m, 1H). LCMS (ESI): m/z = 362 (M+H)+

AVI-3763: H1 NMR (500 MHz,DMSO) δ 12.2 (s, 1H), 9.5-9.28 (m, 1H), 8.41 (s, 1H), 8.24 (dd, J = 8.5, 5.2 Hz, 1H), 7.45 (d, J = 7.1 Hz, 1H), 7.32 (t, J = 7.4 Hz, 1H), 7.28-7.17 (m, 1H), 7.14-7.03 (m, 1H), 5.28–5.06 (m, 1H), 2.57–2.49 (m, 3H), 1.97–1.78 (m, 1H). LCMS (ESI): m/z = 362 (M+H)+

AVI-3764 & AVI-3765



4-Chloro-7-fluoro-9H-pyrimido[4,5-b]indole (222 mg, 1.0 mmol) and 1-amino-5-methyl-pyrrolidin-2-one (196 mg, 1.3 mmol) in a mixture of dioxane*HCl/IPA (1.5 ml/1.5 ml) was stirred at 95°C overnight. Upon completion the mixture was cooled to rt and concentrated under reduced pressure. The crude material was purified by HPLC (40-90% H_2O/MeOH/0.005% HCl) to afford 1-((7-fluoro-9H-pyrimido[4,5-b]indol-4-yl)amino)-5-methylpyrrolidin-2-one (HCl salt, 0.155 g, 46% yield). It was further subjected chiral chromatography (hexane (0.3% DEA): IPA:MeOH, 90:5:5) to obtain **AVI-3765** (39 mg, retention time = 46.18min, 99% optic ee) and **AVI-3764** (36 mg, retention time = 51.98 min, 90% optic ee).

AVI-3765: H1 NMR (500 MHz,DMSO) δ 12.22 (s, 1H), 9.31 (s, 1H), 8.47–8.3 (m, 2H), 7.25 (dd, J = 9.6, 1.9 Hz, 1H), 7.18–7.11 (m, 1H), 4.03 (s, 1H), 2.39–2.26 (m, 3H), 1.7–1.63 (m, 1H), 1.21 (d, J = 6 Hz, 3H). LCMS (ESI): m/z = 300 (M+H)+

AVI-3764: H1 NMR (500 MHz,DMSO) δ 12.22 (s, 1H), 9.31 (s, 1H), 8.45–8.37 (m, 1H), 8.35 (s, 1H), 7.25 (dd, J = 9.4, 2.3 Hz, 1H), 7.2–7.04 (m, 1H), 4.11–3.93 (m, 1H), 2.42–2.19 (m, 3H), 1.75–1.57 (m, 1H), 1.21 (d, J = 6.3 Hz, 3H). LCMS (ESI): m/z = 300 (M+H)+

AVI-4636



A mixture of 4-chloro-7-fluoro-9H-pyrimido[4,5-b]indole (25 mg, 0.11 mmol) and 1-amino-5,5-dimethylpyrrolidin-2-one hydrochloride salt (28 mg, 0.17 mmol) in isopropanol/aqueous 1N HCl (2: 1, 0.6 ml) were heated to 100°C for 18 h. The reaction mixture was purified by reverse phase chromatography (water/acetonitrile/0.1% formic acid) to obtain 10 mg (25%) of 1-((7-fluoro-9H-pyrimido[4,5-b]indol-4-yl)amino)-5,5-dimethylpyrrolidin-2-one formic acid salt (**AVI-4636**) as a white solid. 1H NMR (METHANOL-d4, 400 MHz) δ 8.30 (s, 1H), 8.09 (dd, 1H, J = 5.1, 8.8 Hz), 7.21 (dd, 1H, J = 2.3, 9.4 Hz), 6.97 (t, 1H, J = 9.2 Hz), 2.59-2.63 (m, 2H), 2.20 (br s, 2H), 1.38 (s, 6H). LCMS (ESI): m/z = 314 (M+H)+

AVI-4206



A solution of 3-fluoro-2-nitroaniline (25.00 g, 160 mmol) in THF (500 ml) were added triethylamine (48 g, 480 mmol) and triphosgene (14.2 g, 48 mmol) at 0°C. After stirring for an hour, ethylamine as 2.0 M solution in THF (200 ml) was added. Upon completion of reaction, the mixture was poured into 500 ml of water, extracted with ethyl acetate (3 × 500 ml), the combined organic layers were washed with brine (500 ml), dried over sodium sulfate, filtered, concentrated under reduced pressure and the residue was purified by silica gel column chromatography (0–20% ethyl acetate/hexanes) to afford 1-ethyl-3-(3-fluoro-2-nitrophenyl)urea as yellow solid (22.00 g, yield: 60.57%). LCMS (ESI): m/z = 228.1 (M+H)+

To a solution of 1-ethyl-3-(3-fluoro-2-nitrophenyl)urea (48 g, 211.45 mmol) in DMF (300 ml) were added methyl 2-isocyanoacetate (41.86 g, 422.90 mmol) and potassium carbonate (87.54 g, 634.36 mmol). The solution was stirred at 80°C for 16 hours. The mixture was adjusted to be weakly acidic by 2N HCl, extracted with ethyl acetate (500 ml *3), the combined organic layers were washed with brine (300 ml), dried over sodium sulfate, filtered and concentrated under reduced pressure, the residue was purified via column chromatography on silica gel (0–20% ethyl acetate/hexanes) to afford methyl 2-cyano-2-(3-(3-ethylureido)-2-nitrophenyl)acetate as yellow solid (44.3 g, yield: 68.46%). LCMS (ESI): m/z = 307.2 (M+H)+.

A mixture of methyl 2-cyano-2-(3-(3-ethylureido)-2-nitrophenyl)acetate (42 g, 137.25 mmol) and acetic acid (250 ml) was heated to 40°C. Zinc (89.75 g, 1372.54 mmol) was then added in portions at a rate such that the reaction temperature did not rise above 60°C. After the addition was complete, the reaction mixture was stirred at 60°C for 2 h. The reaction mixture was cooled to room temperature and filtered through a celite pad. The filtrate was concentrated under vacuum. The crude product was purified via column chromatography on silica gel (DCM: MeOH=10:1) to give methyl 2-amino-7-(3-ethylureido)-1H-indole-3-carboxylate as a white solid (16 g, yield: 42.23%). LCMS (ESI): m/z = 277.2 (M+H)+

Methyl 2-amino-7-(3-ethylureido)-1H-indole-3-carboxylate (2.0 g, 7.25 mmol) and formamidine acetate (4.53 g, 43.48 mmol) were heated to 140°C for 1 h. The mixture was cooled to room temperature and diluted with approximately 100 ml of water. The resulting mixture was stirred for 15 min before the solid was collected by filtration. The residue was triturated with DMSO and filtered to afford 1-ethyl-3-(4-hydroxy-9H-pyrimido[4,5-b]indol-8-yl)urea as an off-white solid (1.0 g, yield: 50.8%). 1H NMR (500 MHz, DMSO) δ 12.21 (s, 1H), 11.76 (s, 1H), 8.34 (s, 1H), 8.13 (d, J = 3.5 Hz, 1H), 7.64 (d, J = 7.7 Hz, 1H), 7.40 (d, J = 7.3 Hz, 1H), 7.13 (t, J = 7.8 Hz, 1H), 6.28 (t, J = 5.5 Hz, 1H), 3.26–3.11 (m, 2H), 1.10 (t, J = 7.2 Hz, 3H). LCMS (ESI): m/z = 272.3 (M+H)+

To a solution of 1-ethyl-3-(4-hydroxy-9H-pyrimido[4,5-b]indol-8-yl)urea (500 mg, 1.85 mmol) in THF (20 ml) was added di-*tert*-butyl dicarbonate (1.21 g, 5.54 mmol), DIPEA (955 mg, 7.4 mmol) and DMAP (226 mg, 1.85 mmol). The mixture was stirred at room temperature for 16 hours. The mixture was then concentrated under reduced pressure to give crude *tert*-butyl 4-((*tert*-butoxycarbonyl)oxy)-8-(3-ethylureido)-9H-pyrimido[4,5-b]indole-9-carboxylate as a yellow oil. It was used in the next step without any purification.

A solution of *tert*-butyl 4-((*tert*-butoxycarbonyl)oxy)-8-(3-ethylureido)-9H-pyrimido[4,5-b]indole-9-carboxylate (crude) in $POCl_3$ (10 ml) was stirred at 90°C for 30 min. The solution was concentrated under reduced

pressure and diluted with acetonitrile, then adjusted the pH to 7.0 with ammonium hydroxide slowly. The resulting solid was filtered with vacuum filter and washed with water to give the 1-(4-chloro-9H-pyrimido[4,5-b]indol-8-yl)-3-ethylurea (230 mg, two steps yield: 43.1%) as a light yellow solid. LCMS (ESI): m/z = 290.2 (M+H)+

To a solution of 1-(4-chloro-9H-pyrimido[4,5-b]indol-8-yl)-3-ethylurea (290 mg,1.0 mmol) in dry DMSO(6.0 ml) was added 1-amino-5,5-dimethylpyrrolidin-2-one (192 mg, 1.5 mmol) , $Pd_2(dba)_3$ (92 mg,0.1 mmol), Tri-tert-butylphosphine tetrafluoroborate (44 mg,0.15 mmol) and t-BuONa(240 mg, 2.5 mmol). After stirring at 100°C for 8h, the reaction mixture was filtered and the filtrate was purified by reversed phase chromatography (water /acetonitrile/0.1%TFA). After lyophilization, then silica gel column chromatography (DCM/MeOH=10/1) to obtain 1-(4-((2,2-dimethyl-5-oxopyrrolidin-1-yl)amino)-9H-pyrimido[4,5-b]indol-8-yl)-3-ethylurea (**AVI-4206**) (120 mg, yield:31.5%) as a white solid. 1H NMR (400 MHz, DMSO) δ 11.67 (s, 1H), 9.06 (s, 1H), 8.37 (d, J = 15.7 Hz, 2H), 8.07 (d, J = 7.6 Hz, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.20 (t, J = 7.9 Hz, 1H), 6.28 (t, J = 5.4 Hz, 1H), 3.27–3.10 (m, 2H), 2.42 (t, J = 7.8 Hz, 2H), 2.03 (t, J = 7.8 Hz, 2H), 1.26 (d, J = 21.1 Hz, 6H), 1.11 (t, J = 7.2 Hz, 3H). ^{13}C NMR (DMSO-d6, 100 MHz) δ 171.8, 157.8, 155.9, 155.8, 154.9, 128.6, 125.4, 125.3, 121.2, 120.4, 117.2, 117.1, 96.6, 61.1, 34.8, 34.7, 32.4, 27.8, 26.6, 15.9. LCMS (ESI): m/z = 382 (M+H)+

In vitro validation

X-ray Crystallography:

Mac1 crystals ($P4_3$ construct, residues 3–169) were grown by sitting-drop vapor diffusion in 28% w/v polyethylene glycol (PEG) 3000 and 100 mM N-cyclohexyl-2-aminoethanesulfonic acid (CHES) pH 9.5 as described previously (Schuller et al. 2021; Gahbauer et al. 2023). Compounds prepared in DMSO (100 mM) were added to crystal drops using an Echo 650 acoustic dispenser (Collins et al. 2017) (final concentration of 10 mM). Crystals were incubated at room temperature for 2-4 hours prior to vitrification in liquid nitrogen without additional cryoprotection. X-ray diffraction data were collected at the Advanced Light Source (ALS beamline 8.3.1) or the Stanford Synchrotron Light Source (SSRL beamline 9-2). Data were indexed, integrated and scaled with XDS (Kabsch 2010) and merged with Aimless (Evans and Murshudov 2013). The $P4_3$ Mac1 crystals contain two copies of the protein in the asymmetric unit (chains A and B). The active site of chain A is open, however chain B is blocked by a crystal contact. We previously observed that potent Mac1 inhibitors dissolve crystals, likely through the displacement of the B chain crystal contact (Gahbauer et al. 2023). In addition, crystal packing in the chain A active site restricts movement of the Ala129-Gly134 loop, leading to decreased occupancy for compounds with substituents on the pyrrolidinone. To aid modeling the resulting conformational and compositional disorder, we used the PanDDA method (Pearce et al. 2017) to model ligands where the occupancy was low (<25%, AVI-4051, AVI-3367, AVI-3763, AVI-3762, AVI-3765 and AVI-3764) or where there was substantial disorder (AVI-4636). After modeling ligands, structures were refined using phenix.refine (Liebschner et al. 2019) as described previously (Gahbauer et al. 2023). Data collection settings and statistics are reported in **Supplementary Table 1**.

To achieve higher ligand occupancy for AVI-4206, we co-crystallized an alternative Mac1 construct previously reported to crystallize in P1, $P2_1$ and C2 (residues 2–170) (Michalska et al. 2020; Correy et al. 2022). Crystals grew by sitting-drop vapor diffusion in 200 mM lithium acetate and 20% w/v PEG 3350 with 30 mg/ml Mac1 (1.6 mM) and 3.2 mM AVI-4206 (3.2% DMSO). Crystals were vitrified directly in liquid nitrogen and diffraction data to 0.8 Å were collected at the ALS (beamline 8.3.1). Data were reduced in P1 using the same pipeline as the $P4_3$ crystals. Solvent content analysis suggested that there were two chains in the asymmetric unit. Phases were obtained using Phaser (McCoy et al. 2007) and apo Mac1 coordinates (PDB code 7KQO, chain A). Structural refinementent was performed with phenix.refine following the previously described procedures for ultra-high resolution data (Correy et al. 2022). After several rounds of refinement, positive difference density was clear for a second, relatively low occupancy, conformation of the entire chain A and B, each representing a ~3.1 Å translation relative to the major conformation. Modeling and inspection of the minor conformations suggested that they cannot be occupied simultaneously, therefore they were modeled with distinct alternative location identifiers (altlocs). The major conformation (protein, AVI-4206 and water) was modeled with altloc A and the minor conformations (protein, AVI-4206 and water) were modeled with altlocs

C and D. In addition to the rigid body disorder, there was clear density for a third conformation of the residue 57-75 α-helix. In chain A, this was modeled with altloc B, while the density in chain B was too weak to allow modeling. The F_O-F_C difference electron density maps or PanDDA event maps used to model ligands are shown in **Supplementary Figure 1**.

Inhibition assay:

Inhibition of Mac1 ADP-ribosylhydrolase activity by AVI-219 and AVI-4206 was determined using the NUDT5/AMP-Glo assay (Dasovich et al. 2021; Taha et al. 2023b). The substrate for the ration was human PARP10 (catalytic domain, residues 819-1007), purified and auto-mono-ADP-ribosylated using NAD+ as described previously (Taha et al. 2023b). Briefly, AVI-219 and AVI-4206 were dispensed into 384-well white assay plates (Corning, 3824) using an Echo 650 acoustic dispenser to achieve a final concentration range from 1 mM to 0.4 nM (8 µl reaction volume, 1% DMSO). Purified Mac1 ($P4_3$ construct, 2 µl, 10 nM final concentration) and NUDT5 (2 µl, 100 nM final concentration) were added to wells and the plates were incubated for five minutes at room temperature. Mono-ADP-ribosylated PARP10 was added to wells (4 µl, 2 µM final concentration) and the plates were incubated at room temperature for an additional hour. The concentration of AMP was measured with an AMP-Glo assay kit (Promega, V5011) following the manufacturer's instructions using a BioTek Synergy HTX plate reader. Percentage inhibition was calculated relative to control wells containing no inhibitor (DMSO only, 0% inhibition) or no Mac1 (100% inhibition) and IC_{50} values were determined by fitting a four-parameter sigmoidal dose-response equation using GraphPad Prism (version 10.1.1), with the top and bottom constrained to 100 and 0% inhibition respectively. Data are presented as the mean ± SD of four technical replicates. A control reaction with increasing concentrations of Mac1 indicated that <50% of the mono-ADP-ribosylated PARP10 was hydrolyzed in the 0% inhibition control (**Supplementary Figure 2**). In addition, a counterscreen to test for NUDT5 inhibition or assay interference was performed with identical reactions, except Mac1 was omitted and ADP-ribose was added to a final concentration of 2 µM (Sigma, A0752).

HTRF:

Binding of the compounds to macrodomain proteins was assessed by the displacement of an ADPr conjugated biotin peptide from His_6-tagged protein using an HTRF-technology based screening assay which was performed as previously described (Schuller et al. 2021). The protein sequences used for SARS-CoV-2 Mac1, and the human macrodomains TARG1 and MacroD2, are listed in **Supplementary Table 5**. All proteins were expressed and purified as described previously for SARS-CoV-2 Mac1 (Schuller et al. 2021). Compounds were dispensed into ProxiPlate-384 Plus (PerkinElmer) assay plates using an Echo 650 Liquid Handler (Beckman Coulter). Binding assays were conducted in a final volume of 16 µl with 12.5 nM NSP3 Mac1 protein, 200 nM peptide ARTK(Bio)QTARK(Aoa- RADP)S (Cambridge Peptides), 1:20000 Eu^{3+} cryptate conjugated to a His_6-specific antibody (HTRF donor, PerkinElmer AD0402) and 1:500 Streptavidin-XL665 (HTRF acceptor, PerkinElmer 610SAXLB) in assay buffer (25 mM 4-(2-hydroxyethyl)-1-piperazine-1-ethanesulfonic acid (HEPES) pH 7.0, 20 mM NaCl, 0.05% bovine serum albumin and 0.05% Tween-20). TARG1 and MacroD2 binding were measured at 25nM and 12.5 nM, respectively. Assay reagents were dispensed manually into plates using an electronic multichannel pipette. Macrodomain protein and peptide were dispensed and preincubated for 30 min at room temperature before HTRF reagents were added. Fluorescence was measured after a 1 hour incubation at room temperature using a Perkin Elmer EnVision 2105-0010 Dual Detector Multimode microplate reader with dual emission protocol (A = excitation of 320 nm, emission of 665 nm, and B = excitation of 320 nm, emission of 620 nm). Compounds were tested in triplicate in a 14-point dose response. Raw data were processed to give an HTRF ratio (channel A/B × 10,000), which was used to generate IC_{50} curves. The IC_{50} values were determined by nonlinear regression using GraphPad Prism (version 10.1.1). Data are presented as mean ± SD of three technical replicates.

CETSA:

Cellular target engagement of compounds was assessed using a CETSA-nLuc or CETSA-WB assay (Martinez et al. 2018). The SARS-CoV-2 Mac1 macrodomain was cloned into pcDNA3.1 by Genscript with both an N-terminal 3XFLAG tag and a C-terminal HiBiT tag as listed in **Supplementary Table 5**. A 2A mKate

was included to identify successfully transfected cells (e.g., pcDNA-3xFLAG-Mac1^{WT}-nLuc-t2A-mKate2). Plasmids were reverse transfected into A549 cells using Lipofectamine 3000 transfection reagent (Thermo). After 48 h, cells were harvested by trypsinization and resuspended at 1×10^6 cells/ml in CETSA buffer (1× DPBS (with $CaCl_2$ and $MgCl_2$), 1 g/l glucose and 1× protease inhibitor cocktail (Roche, 5892970001). Cells were treated in microcentrifuge tubes with compound or DMSO and incubated at 37°C for 1 h.

For CETSA-nLuc experiments, 30 µl of suspended cells were dispensed into a 96-well PCR plate (Biorad) and heated for 3.5 min using a preheated gradient thermal cycler (Eppendorf). A Nano-Glo® HiBiT Lytic Detection System (Promega) was used to quantify HiBiT-tagged proteins in cell lysates. 30 µl of a mixture containing Lytic Buffer, LgBiT protein, HiBiT Lytic Substrate were added to the cell suspension, and luminescence intensity was measured using a Biotek Synergy H1. Luminescence values for each sample were normalized to the lowest temperature on the range and T_{agg} (T-aggregate) values were determined by fitting data with a four-parameter sigmoidal dose-response equation using non-linear regression in GraphPad Prism (version 10.1.1). Delta values were calculated by subtracting the T_{agg}^{DMSO} value from the T_{agg}^{drug} value. Data are presented as mean ± SD of two technical replicates.

For CETSA-WB experiments, 45 µl of suspended cells were dispensed into PCR strip tubes and heated for 3.5 min using a pre-heated gradient thermal cycler (Eppendorf). Samples were then placed in an aluminum PCR block on a dry ice/ethanol bath for 3 min, followed by incubating at 37°C for 3 min, and vortexing for 3 seconds. This freeze-thaw cycle was repeated three more times. Insoluble proteins were transferred to a 1.5 ml microcentrifuge tube, separated by centrifugation (20,000*g*, 15 min, 4°C) and 40 µl of supernatant corresponding to soluble proteins was kept for WB. Samples were separated on an SDS-polyacrylamide gel and transferred to a PVDF membrane. The following antibodies were used for immunoblotting: anti-FLAG antibody (Sigma, F1804, 1:1000 overnight), anti-mouse HRP antibody (CST, 7076S, 1:3000 for 1 hour). Images were captured using the Azure c600 Western Blot Imaging System, quantified using ImageJ and plotted as above.

Cellular and Organoid studies

SARS-CoV-2 culture:

As described in our previous report (Taha et al. 2023b), the pBAC SARS-CoV-2 WT (WA1) and N40D mutant constructs on WA1 background were made by co-transfecting them with an N expression vector into BHK-21 cells. Following three days of transfection the cell supernatants were used to infect Vero cells stably expressing TMPRSS2, followed by passaging to achieve a high viral titer. All viruses generated or used in this study were verified by NGS using the ARTIC Network's protocol. A previously reported mNeon SARS-CoV-2 infectious clone (ic-SARS-CoV-2-mNG) (Xie et al. 2020) was passaged on Vero-TMPRSS2 and used for Incucyte-based antiviral assays.

Cells:

BHK-21 obtained from ATCC, were grown in DMEM (Corning) with 10% fetal bovine serum (FBS) (GeminiBio), 1× Glutamax (Corning), and 1× Penicillin-Streptomycin (Corning) at 37°C in a 5% CO_2 atmosphere. A549-ACE2h cells were generated by stably expressing hACE2 (Khalid et al. 2024) and further selecting for high ACE2 expression levels via FACS with Alexa Fluor® 647 conjugated to a hACE2-specific antibody (FAB9332R, R&D systems). These cells were cultured in DMEM supplemented with 10% FBS, 10 µg/ml blasticidin (Sigma), 1× NEAA (Gibco), and 1% L-glutamine (Corning) at 37°C in a 5% CO_2 atmosphere. Vero cells that stably overexpress human TMPRSS2 (Vero TMPRSS2), a gift from the Whelan lab (Case et al. 2020), were cultured under the same conditions. Additionally, Vero cells that stably express human ACE2 and TMPRSS2 (VAT), provided by A. Creanga and B. Graham from the NIH, were maintained in DMEM with 10% FBS, 1× Penicillin-Streptomycin, and 10 µg/ml puromycin at 37°C in a 5% CO_2 atmosphere. A549 cells obtained from ATCC, were grown in DMEM Glutamax (Gibco) with 10% fetal bovine serum (FBS) (GeminiBio), and 1× Penicillin-Streptomycin (Corning) at 37°C in a 5% CO_2 atmosphere.

704

705 **Human airway organoids:**

706 Human lung tissues were used to generate self-organizing 3D human airway organoids (HAO) consisting of
707 basal cells, multi-ciliated epithelial cells, mucus-producing secretory cells, and club cells. As described
708 previously (Suryawanshi et al. 2022; Taha et al. 2023b), the human lung tissues obtained from Matthay lab
709 were dissociated to single cells using enzymatic digestion. The isolated single cells were resuspended in
710 Basement Membrane Extract (BME, R&D biosystems), to form a BME droplet containing cells which was
711 submerged in HAO medium consisting 1 mM HEPES (Corning), 1× GlutaMAX (Gibco), 1× Penicillin-
712 Streptomycin (Corning), 10% R-spondin1 conditioned medium, 1% B27 (Gibco), 25 ng/ml noggin (Peprotech),
713 1.25 mM N-acetylcysteine (Sigma-Aldrich), 10 mM nicotinamide (Sigma-Aldrich), 5 nM heregulin-β1
714 (Peprotech), and 100 µg/ml Primocin (InvivoGen) in DMEM. This HAO medium was also supplemented with
715 5 µM Y-27632, 500 nM A83-01, 500 nM SB202190, 25 ng/ml FGF7, and 100 ng/ml FGF10 (all obtained from
716 Stem Cell Technologies). After sufficient growth of HAO's, in order to differentiate the HAO cells the HAO
717 medium was replaced with equal proportion of HAO medium and PneumaCult-ALI medium (Stem cell
718 Technologies).

719

720 **SARS-CoV-2 replicon assay:**

721 The SARS-CoV-2 replicon assay was conducted as described previously (Taha et al. 2023a, 2023b). Briefly,
722 the pBAC SARS-CoV-2 ΔSpike WT or nsp3 Mac1 N40D modified plasmids (40 µg), were transfected into
723 BHK-21 fibroblast cells along with N and S expression vectors (20 µg each) in a 15-cm^2 tissue culture dish.
724 The culture media was replaced with fresh growth medium 12 hours post-transfection. The media containing
725 single-round infectious particles was collected and 0.45 µm-filtered 72 hours post-transfection and stored at
726 –80 C until use.

727 Vero-ACE2-TMPRSS2 (VAT) and A549 $ACE2^h$ cells were plated $2.5x10^4$ cells per well in 96-well plate in
728 media containing 0, 1000, or 10000 IU/ml of IFN-γ. After 16 hours, the media was replaced with 50 µl media
729 containing 5x the final desired concentration of IFN-γ and AVI-4206. After 2 hours, 200 µl of supernatant
730 containing WA1 or WA1 nsp3 Mac1 N40D single-round infectious particles was added. After 8 hours, the cells
731 were washed with 200 µl culture medium and 100 µl of culture medium was added. After 16 hours, 50 µl from
732 each well was transferred to a white 96-well plate to measure nanoluciferase activity by adding 50 µl of Nano-
733 Glo luciferase assay buffer and substrate and analyzed on an Infinite M Plex plate reader (Tecan).

734

735 **SARS-CoV-2 *in vitro* antiviral assay:**

736 Antiviral activity of compounds was assessed using the Incucyte® live-cell analysis system. $2x10^4$ A549-
737 ACE2h cells per well were seeded in Edge 2.0 96-well plates filled with 1.5 ml PBS in the outer moats and
738 100 µl in-between wells and incubated at 37°C and 5% CO_2. The next day, cells were pre-treated with
739 compounds for 2 hours, followed by the removal of the compounds and infection with 50 µl of icSARS-CoV-
740 2-mNG at a MOI 0.1 for 2 hours. Subsequently, virus inoculum was removed and fresh compounds diluted in
741 DMEM (10% FBS, 1% L-Glutamine, 1× P/S, 1× NEAA, Incucyte® Cytotox Dye) were added. Infected cells
742 were placed in an Incucyte S3 (Sartorius) and infection and cell death were measured over 48 hours at 1-
743 hour intervals using a 10x objective, capturing 3 images per well at each time point under cell maintenance
744 conditions (37°C, 5% CO_2). Infection and cell death were quantified as Total Green Object Integrated Intensity
745 (300 ms acquisition time) and Red Object Integrated Intensity (400 ms acquisition time), respectively. After
746 in-built software analysis, raw data was exported and antiviral efficacy was determined as the percentage of
747 viral replication normalized to the vehicle control. Nirmatrelvir (HY-138687, MedChemExpress) and
748 uninfected cells were used as intra-assay positive and negative controls, respectively. Unless otherwise
749 stated, experiments were conducted in triplicate with 3 technical replicates. EC_{50} values were calculated using
750 GraphPad PRISM 10 (La Jolla, CA, USA) employing a dose-response inhibition equation with a non-linear fit
751 regression model.

752

753 **Antiviral efficacy in human airway organoids:**

754 The differentiated HAOs were utilized to analyze the dose-dependent anti SARS-CoV-2 efficacy of AVI-4206.
755 Briefly, 100,000 cells of differentiated HAOs were seeded in a V-bottom plate (Greiner Bio-One). The cells
756 were pretreated for 2 hours prior to infection with various concentrations of AVI-4206 (0, 0.16 μM, 0.8 μM, 4
757 μM, 20 μM, 100 μM). After pretreatment, the HAOs were washed and infected with SARS-CoV-2 WA1 at a
758 multiplicity of infection (MOI) of 1. A WA1-N40D mutant strain lacking the macrodomain activity was used as
759 a positive control. Following 2 hours of infection, the HAOs were washed three times. Each washing step
760 involved replacing the media with PBS and centrifuging the cells at 1000 rpm for 3 minutes. After three
761 washes, the PBS was replaced with 100 μl of HAO differentiation medium, with or without varying
762 concentrations of AVI-4206, and the plate was incubated for 72 hours at 37°C with 5% CO2. Supernatants
763 collected at 24-hour intervals were used to analyze mature virus particle formation via plaque assay.
764

765 **Drug cytotoxicity assay:**
766 A549-ACE2h cells were seeded and incubated as for the in vitro antiviral assay. Cells were treated with
767 compounds at the respective concentrations and vehicle control for 50 hours at 37°C and 5% CO_2.
768 Subsequently, Cell Titer-Glo® reagent was added in a 1:1 ratio to the cells and incubated at room temperature
769 for 5 minutes before transferring 100 μl of the mixture to a white 96-well plate. Luciferase activity was
770 measured using an Infinite M Plex plate reader (Tecan). Cell viability was determined as the percentage of
771 viability normalized to the vehicle control. Compound cytotoxicity was assessed in parallel with infection
772 experiments using cells of the same passage.
773

774 **Thermal proteome profiling (TPP) assay:**

775 Pelleted A549 cells were resuspended in extraction buffer (1× PBS + phosphatase and protease inhibitors
776 (phosSTOP (Roche) and cOmplete Mini Protease Inhibitor Cocktail (Roche)) with gentle pipetting followed by
777 rotation at 4°C for 30 minutes. Lysates were centrifuged at 1000*g* for 10 minutes at 4°C and supernatant was
778 transferred to new tubes. Recombinant Mac1 was spiked into lysate to a final concentration of 0.05 μM.
779 Lysates + Mac1 were incubated with compound at a final concentration of 100 μM AVI-4206 or DMSO for 30
780 minutes at 25°C. Lysates (2 replicates per condition) were distributed into 10 aliquots (20 μl each) in PCR
781 tubes. Samples were heated from 37°C to 64°C in 3°C increments on a BioRad C1000 Touch Thermal cycler,
782 and held for four minutes at the specified temperature. Samples were held at room temperature for three
783 minutes. Samples were then subjected to 2 cycles of flash freezing and thawing at 35°C. Aggregated proteins
784 were removed by centrifugation at 20,000*g* for 60 minutes. 20 μl of lysis buffer (8 M urea, 100 mM Tris, pH
785 ~7.5) was added to each well and samples were incubated for 30 minutes at room temperature. Samples
786 were reduced and alkylated by the addition of TCEP (100mM final) and 2-chloroacetamide (44mM final)
787 followed by incubation at room temperature for 30 minutes. Urea concentration was diluted to 1 M by the
788 addition of 100 mM tris (pH ~7.5). Samples were digested overnight with LysC (Wako, 1:100 enzyme: protein
789 ratio) and trypsin (Promega, 1:50 enzyme:protein ratio). Samples were desalted with a 96-well mini 20MG
790 PROTO 300 C18 plate (HNS S18V, The Nest Group) according to manufacturer's directions. Peptide
791 concentration was determined by NanoDrop (Thermo).

792 Following digestion, peptides were injected onto a timsTOF SCP (Bruker) connected to either an EASY-nLC
793 1200 system (Thermo) or VanquishNeo (Thermo). Peptides were separated on a PepSep reverse-phase C18
794 column (1.9 μm particles, 15 cm, 150 mm ID) (Bruker) with a gradient of 5-28% buffer B (0.1% formic acid in
795 acetonitrile) over buffer A (0.1% formic acid in water) over 20 minutes, an increase to 32% B in 3 minutes,
796 and held at 95% B for 7 minutes. DIA-PASEF analyses were acquired from 100 to 1700 m/z over a 1/Kø of
797 0.70 to 1.30 Vs/cm^2, with a ramp and accumulation time set to 75 ms. Library DDA PASEF runs were collected
798 over the same m/z and 1/Kø range and a cycle time of 1.9 s.

799 All data was searched against the Uniprot Human database (downloaded 05/25/23) appended with the SARS-
800 CoV-2 database (downloaded 02/20/2024) using a combined DDA and DIA library in Spectronaut (Biognosys,
801 version 19.0). Default settings, including trypsin digestion, variable modifications of methionine oxidation and
802 N-termini acetylation, and fixed modification of cysteine carbamidomethylation, were used. Missing values
803 were imputed for each run using background intensity. Data was filtered to obtain a false discovery rate of

1% at the peptide spectrum match and protein level. Lysate experiments were normalized to the lowest temperature (37°C) and melting points were determined in R using the Inflect package (McCracken et al. 2021).

PK and *In vivo* studies

ADMET target and kinase studies:

The kinase assessment was performed using contract services by Eurofins using their scanEDGE KINOMEscan Assay Platform (Study Code: US073-0032699). Assessment of ADMET targets (cardiac channel profiling, CYP induction, peptidase selectivity panel and secondary pharmacology profiling) was performed via NIAID's suite of preclinical services for in vitro assessment (Contract No. HHSN272201800007I/75N93022F00001).

Pharmacokinetic Studies:

The pharmacokinetic study of AVI-4206 with IV (10 mg/kg), PO (50 mg/kg), and IP (100 mg/kg) dosing (Fig. 4B and Supplementary Table 2) was performed in male CD1 mice (n = 3 per group) using a formulation of 10% DMSO: 50% PEG 400: 40% of a 20% HP-β-CD in water. Microsampling (40 ml) via facial vein was performed at 0, 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h into K_2EDTA tubes. The blood samples were collected and centrifuged to obtain plasma (8000 rpm, 5 min) within 15 minutes post sampling. Nine blood samples were collected from each mouse; three samples were collected for each time point. Data was processed by Phoenix WinNonlin (version 8.3); samples below the limit of quantitation were excluded in the PK parameters and mean concentration calculation.

Animal experiments:

All the mice experiments were approved (AN169239-01) by the Institutional Animal Care and Use committees at the University of California, San Francisco and Gladstone Institutes and performed in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animal. For screening of lead Macrodomain inhibitors we employed a transgenic mice model capable of expressing human ACE2. Female mice were divided into three groups: test, positive control, and negative control. The positive control groups were infected (5×10^2 PFUs) with the N40D mutant of SARS-CoV-2, while the other mice were infected with the WA1 strain. Intraperitoneal treatments were administered twice daily which began at a day prior infection and continued until 5 days post-infection, with close monitoring for disease parameters such as weight loss, hypothermia, and hunched posture. At 4 and 7 days post-infection, a subset of mice from each group was euthanized, and their lungs and brain tissues were harvested for virus titration by plaque assay and cytokine expression.

Plaque assay:

The mature virus particles in the lung homogenates were analyzed using plaque assay. Briefly, VAT cells were seeded in a 12-well plate and incubated overnight. The cells were inoculated with 10 to 10^6 dilutions of the respective lung homogenates. After 1h incubation, the lung homogenates in the wells were overlaid with 2.5% Avicel (RC-591, Dupont). And the plates were incubated at 370C and 5% CO_2 for 48h . After incubation the overlay media was removed and the cells were fixed in 10% formalin. The plaques were visualized by staining the cells with crystal violet. Data analysis was performed by using GraphPad Prism version 10.

Cytokine estimation:

Lung homogenates were clarified by centrifugation at 6000 rpm for 10 mins and were used for enzyme linked immunosorbent assay (ELISA) based cytokine estimation. The assays were performed as per manufacturer's protocol for IP-10 (Invitrogen, catalog#BMS56018 and BMS6018TEN), IL-2 (Invitrogen, catalog#BMS601, and BMS601TEN), IL-6 (Invitrogen, catalog#BMS103-2, BMS603-2TWO, and BMS603-2TEN), TNF-a (Invitrogen, catalog#BMS607-3 and BMS607-3TEN), IL1b (Invitrogen, catalog#BMS6002-2 and BMS6002-2TEN).

Data and Materials Availability

X-ray structures have been deposited in the Protein Data Bank as: 9CXY (AVI-1500), 9CXZ (AVI-1501), 7HC4 (AVI-3367), 7HC5 (AVI-3765), 7HC6 (AVI-3764), 7HC7 (AVI-4051), 7HC8 (AVI-3763), 7HC9 (AVI-3762), 7HCA (AVI-4636), 9CY0 (AVI-4206).

All other data supporting the findings of the present study are available in the article, extended data and supplementary figures, or are available from the corresponding authors on request.

Competing Interests

A.R.R, P.J., R.L.G., T.T., M.R., J.S.F., G.J.C., B.K.S., R.J.N, A.A., M.D., P.C.O., Y.D.P., N.K., M.O., T.Y.T., R.S., F.Z.B., and M.M. are listed as inventors on a patent application describing small molecule macrodomain inhibitors, which includes compounds described herein. T.Y.T and M.O. are listed as inventors on a patent application filed by the Gladstone Institutes that covers the use of pGLUE to generate SARS-CoV-2 infectious clones and replicons.

The Krogan laboratory has received research support from Vir Biotechnology, F. Hoffmann-La Roche and Rezo Therapeutics. N.J.K. has financially compensated consulting agreements with Maze Therapeutics and Interline Therapeutics. He is on the Board of Directors and is President of Rezo Therapeutics and is a shareholder in Tenaya Therapeutics, Maze Therapeutics, Rezo Therapeutics, GEn1E Lifesciences and Interline Therapeutics. B.K.S is co-founder of BlueDolphin LLC, Epiodyne Inc, and Deep Apple Therapeutics, Inc., and serves on the SRB of Genentech, the SAB of Schrodinger LLC, and the SAB of Vilya Therapeutics. M.O. is a cofounder of Directbio and board member of InVisishield. A.R.R. is a co-founder of TheRas, Elgia Therapeutics, and Tatara Therapeutics, and receives sponsored research support from Merck, Sharp and Dohme. A.A. is a co-founder of Tango Therapeutics, Azkarra Therapeutics and Kytarro; a member of the board of Cytomx, Ovibio Corporation, Cambridge Science Corporation; a member of the scientific advisory board of Genentech, GLAdiator, Circle, Bluestar/Clearnote Health, Earli, Ambagon, Phoenix Molecular Designs, Yingli/280Bio, Trial Library, ORIC and HAP10; a consultant for ProLynx, Next RNA and Novartis; receives research support from SPARC; and holds patents on the use of PARP inhibitors held jointly with AstraZeneca from which he has benefited financially (and may do so in the future). J.S.F. is a consultant to, shareholder of, and receives sponsored research support from Relay Therapeutics.

References

Alhammad YM, Parthasarathy S, Ghimire R, Kerr CM, O'Connor JJ, Pfannenstiel JJ, et al. SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in cell culture and in mice. Proc Natl Acad Sci U S A. 2023 Aug 29;120(35):e2302083120.

Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020 Jul;583(7818):830–3.

Case JB, Rothlauf PW, Chen RE, Liu Z, Zhao H, Kim AS, et al. Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. Cell Host Microbe. 2020 Sep 9;28(3):475–85.e5.

Collins PM, Ng JT, Talon R, Nekrosiute K, Krojer T, Douangamath A, et al. Gentle, fast and effective crystal soaking by acoustic dispensing. Acta Crystallogr D Struct Biol. 2017 Mar 1;73(Pt 3):246–55.

Correy GJ, Kneller DW, Phillips G, Pant S, Russi S, Cohen AE, et al. The mechanisms of catalysis and ligand binding for the SARS-CoV-2 NSP3 macrodomain from neutron and x-ray diffraction at room

temperature. Sci Adv. 2022 May 27;8(21):eabo5083.

Dasovich M, Leung AKL. PARPs and ADP-ribosylation: Deciphering the complexity with molecular tools. Mol Cell. 2023 May 18;83(10):1552–72.

Dasovich M, Zhuo J, Goodman JA, Thomas A, McPherson RL, Jayabalan AK, et al. High-Throughput Activity Assay for Screening Inhibitors of the SARS-CoV-2 Mac1 Macrodomain. ACS Chem Biol [Internet]. 2021 Dec 14; Available from: http://dx.doi.org/10.1021/acschembio.1c00721

von Delft A, Hall MD, Kwong AD, Purcell LA, Saikatendu KS, Schmitz U, et al. Accelerating antiviral drug discovery: lessons from COVID-19. Nat Rev Drug Discov. 2023 Jul;22(7):585–603.

Evans PR, Murshudov GN. How good are my data and what is the resolution? Acta Crystallogr D Biol Crystallogr. 2013 Jul;69(Pt 7):1204–14.

Gahbauer S, Correy GJ, Schuller M, Ferla MP, Doruk YU, Rachman M, et al. Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 macrodomain of SARS-CoV-2. Proc Natl Acad Sci U S A. 2023 Jan 10;120(2):e2212931120.

Kabsch W. XDS. Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125–32.

Kar P, Chatrin C, Đukić N, Suyari O, Schuller M, Zhu K, et al. PARP14 and PARP9/DTX3L regulate interferon-induced ADP-ribosylation. EMBO J [Internet]. 2024 Jun 4; Available from: http://dx.doi.org/10.1038/s44318-024-00126-0

Kasson S, Dharmapriya N, Kim IK. Selective monitoring of the protein-free ADP-ribose released by ADP-ribosylation reversal enzymes. PLoS One. 2021 Jun 30;16(6):e0254022.

Kerr CM, Parthasarathy S, Schwarting N, O'Connor JJ, Pfannenstiel JJ, Giri E, et al. PARP12 is required to repress the replication of a Mac1 mutant coronavirus in a cell- and tissue-specific manner. J Virol. 2023 Sep 28;97(9):e0088523.

Kerr CM, Pfannenstiel JJ, Alhammad YM, O'Connor JJ, Ghimire R, Shrestha R, et al. Mutation of a highly conserved isoleucine residue in loop 2 of several β-coronavirus macrodomains indicates that enhanced ADP-ribose binding is detrimental to infection. bioRxiv [Internet]. 2024 Jul 12; Available from: http://dx.doi.org/10.1101/2024.01.03.574082

Khalid MM, Chen IP, Soveg FS, Taha TY, Tabata T, Suryawanshi RK, et al. Regulation of virion production by the ORF8 signal peptide across SARS-CoV-2 variants [Internet]. bioRxiv. 2024 [cited 2024 Jul 22]. p. 2024.03.05.583578. Available from: https://www.biorxiv.org/content/10.1101/2024.03.05.583578v1

Kim YM, Shin EC. Type I and III interferon responses in SARS-CoV-2 infection. Exp Mol Med. 2021 May;53(5):750–60.

Lee AA, Amick I, Aschenbrenner JC, Barr HM, Benjamin J, Brandis A, et al. Discovery of potent SARS-CoV-2 nsp3 macrodomain inhibitors uncovers lack of translation to cellular antiviral response [Internet]. bioRxiv. 2024 [cited 2024 Aug 27]. p. 2024.08.19.608619. Available from: https://www.biorxiv.org/content/10.1101/2024.08.19.608619v1.abstract

Leung AKL, Griffin DE, Bosch J, Fehr AR. The Conserved Macrodomain Is a Potential Therapeutic Target for Coronaviruses and Alphaviruses. Pathogens [Internet]. 2022 Jan 14;11(1). Available from: http://dx.doi.org/10.3390/pathogens11010094

Li C, Huang J, Yu Y, Wan Z, Chiu MC, Liu X, et al. Human airway and nasal organoids reveal escalating replicative fitness of SARS-CoV-2 emerging variants. Proc Natl Acad Sci U S A. 2023a Apr 25;120(17):e2300376120.

933 Liebschner D, Afonine PV, Baker ML, Bunkóczi G, Chen VB, Croll TI, et al. Macromolecular structure
934 determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr D
935 Struct Biol. 2019 Oct 1;75(Pt 10):861–77.

936 Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: progress and lessons
937 learned. Nat Rev Drug Discov. 2023b Jun;22(6):449–75.

938 Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017 Mar
939 17;355(6330):1152–8.

940 Martinez NJ, Asawa RR, Cyr MG, Zakharov A, Urban DJ, Roth JS, et al. A widely-applicable high-
941 throughput cellular thermal shift assay (CETSA) using split Nano Luciferase. Sci Rep. 2018 Jun
942 21;8(1):9472.

943 McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic
944 software. J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658–74.

945 McCracken NA, Peck Justice SA, Wijeratne AB, Mosley AL. Inflect: Optimizing Computational Workflows for
946 Thermal Proteome Profiling Data Analysis. J Proteome Res. 2021 Apr 2;20(4):1874–88.

947 McPherson RL, Abraham R, Sreekumar E, Ong SE, Cheng SJ, Baxter VK, et al. ADP-ribosylhydrolase
948 activity of Chikungunya virus macrodomain is critical for virus replication and virulence. Proc Natl Acad
949 Sci U S A. 2017 Feb 14;114(7):1666–71.

950 Michalska K, Kim Y, Jedrzejczak R, Maltseva NI, Stols L, Endres M, et al. Crystal structures of SARS-CoV-
951 2 ADP-ribose phosphatase: from the apo form to ligand complexes. IUCrJ. 2020 Sep 1;7(Pt 5):814–24.

952 Minkoff JM, tenOever B. Innate immune evasion strategies of SARS-CoV-2. Nat Rev Microbiol. 2023
953 Mar;21(3):178–94.

954 Neufeldt CJ, Cerikan B, Cortese M, Frankish J, Lee JY, Plociennikowska A, et al. SARS-CoV-2 infection
955 induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB. Commun Biol. 2022
956 Jan 12;5(1):45.

957 O'Connor JJ, Ferraris D, Fehr AR. An Update on the Current State of SARS-CoV-2 Mac1 Inhibitors.
958 Pathogens [Internet]. 2023 Oct 7;12(10). Available from: http://dx.doi.org/10.3390/pathogens12101221

959 Oladunni FS, Park JG, Pino PA, Gonzalez O, Akhter A, Allué-Guardia A, et al. Lethality of SARS-CoV-2
960 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat Commun. 2020 Nov
961 30;11(1):6122.

962 Papini C, Ullah I, Ranjan AP, Zhang S, Wu Q, Spasov KA, et al. Proof-of-concept studies with a
963 computationally designed M^{pro} inhibitor as a synergistic combination regimen alternative to Paxlovid.
964 Proc Natl Acad Sci U S A. 2024 Apr 23;121(17):e2320713121.

965 Parthasarathy S, Saenjamsai P, Hao H, Ferkul A, Pfannenstiel JJ, Suder EL, et al. PARP14 is pro- and anti-
966 viral host factor that promotes IFN production and affects the replication of multiple viruses. bioRxiv
967 [Internet]. 2024 Apr 26; Available from: http://dx.doi.org/10.1101/2024.04.26.591186

968 Pearce NM, Krojer T, Bradley AR, Collins P, Nowak RP, Talon R, et al. A multi-crystal method for extracting
969 obscured crystallographic states from conventionally uninterpretable electron density. Nat Commun.
970 2017 Apr 24;8:15123.

971 Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005
972 May;5(5):375–86.

973 Robertson SJ, Bedard O, McNally KL, Shaia C, Clancy CS, Lewis M, et al. Genetically diverse mouse
974 models of SARS-CoV-2 infection reproduce clinical variation in type I interferon and cytokine responses
975 in COVID-19. Nat Commun. 2023 Jul 25;14(1):4481.

976 Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, Heo I, Böttinger L, Klay D, et al. Long-term
977 expanding human airway organoids for disease modeling. EMBO J [Internet]. 2019 Feb 15;38(4).
978 Available from: http://dx.doi.org/10.15252/embj.2018100300

979 Savitski MM, Reinhard FBM, Franken H, Werner T, Savitski MF, Eberhard D, et al. Tracking cancer drugs in
980 living cells by thermal profiling of the proteome. Science. 2014 Oct 3;346(6205):1255784.

981 Schuller M, Correy GJ, Gahbauer S, Fearon D, Wu T, Díaz RE, et al. Fragment binding to the Nsp3
982 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking.
983 Sci Adv [Internet]. 2021 Apr;7(16). Available from: http://dx.doi.org/10.1126/sciadv.abf8711

984 Schuller M, Zarganes-Tzitzikas T, Bennett J, De Cesco S, Fearon D, von Delft F, et al. Discovery and
985 Development Strategies for SARS-CoV-2 NSP3 Macrodomain Inhibitors. Pathogens [Internet]. 2023
986 Feb 15;12(2). Available from: http://dx.doi.org/10.3390/pathogens12020324

987 Simoneau CR, Chen PY, Xing GK, Hayashi JM, Chen IP, Khalid MM, et al. NF-κB inhibitor alpha controls
988 SARS-CoV-2 infection in ACE2-overexpressing human airway organoids. Sci Rep. 2024 Jul
989 4;14(1):15351.

990 Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 2020 Mar 1;34(5-6):360–94.

991 Suryawanshi RK, Chen IP, Ma T, Syed AM, Brazer N, Saldhi P, et al. Limited cross-variant immunity from
992 SARS-CoV-2 Omicron without vaccination. Nature. 2022 Jul;607(7918):351–5.

993 Taha TY, Chen IP, Hayashi JM, Tabata T, Walcott K, Kimmerly GR, et al. Rapid assembly of SARS-CoV-2
994 genomes reveals attenuation of the Omicron BA.1 variant through NSP6. Nat Commun. 2023a Apr
995 21;14(1):2308.

996 Taha TY, Suryawanshi RK, Chen IP, Correy GJ, McCavitt-Malvido M, O'Leary PC, et al. A single
997 inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication in
998 vivo. PLoS Pathog. 2023b Aug;19(8):e1011614.

999 Tan B, Zhang X, Ansari A, Jadhav P, Tan H, Li K, et al. Design of a SARS-CoV-2 papain-like protease
000 inhibitor with antiviral efficacy in a mouse model. Science. 2024 Mar 29;383(6690):1434–40.

001 Voth LS, O'Connor JJ, Kerr CM, Doerger E, Schwarting N, Sperstad P, et al. Unique Mutations in the
002 Murine Hepatitis Virus Macrodomain Differentially Attenuate Virus Replication, Indicating Multiple Roles
003 for the Macrodomain in Coronavirus Replication. J Virol. 2021 Jul 12;95(15):e0076621.

004 Wazir S, Parviainen TAO, Pfannenstiel JJ, Duong MTH, Cluff D, Sowa ST, et al. Discovery of 2-Amide-3-
005 methylester Thiophenes that Target SARS-CoV-2 Mac1 and Repress Coronavirus Replication,
006 Validating Mac1 as an Antiviral Target. J Med Chem. 2024 Apr 25;67(8):6519–36.

007 Xie X, Muruato A, Lokugamage KG, Narayanan K, Zhang X, Zou J, et al. An Infectious cDNA Clone of
008 SARS-CoV-2. Cell Host Microbe. 2020 May 13;27(5):841–8.e3.

009 Zheng J, Wong LYR, Li K, Verma AK, Ortiz ME, Wohlford-Lenane C, et al. COVID-19 treatments and
010 pathogenesis including anosmia in K18-hACE2 mice. Nature. 2021 Jan;589(7843):603–7.

011 Tino W. Sanchez, Michael H. Ronzetti, Ashley E. Owens, Maria Antony, Ty Voss, Eric Wallgren, Daniel
012 Talley, Krishna Balakrishnan, Sebastian E. Leyes Porello, Ganesha Rai, Juan J. Marugan, Samuel G.
013 Michael, Bolormaa Baljinnyam, Noel Southall, Anton Simeonov, and Mark J. Henderson. 2022. "Real-

014 Time Cellular Thermal Shift Assay to Monitor Target Engagement". *ACS Chemical Biology 17* (9),
015 2471-2482
016 DOI: 10.1021/acschembio.2c00334
017
018

Supplementary information

Supplementary Table1 - X-ray data collection and refinement deposition statistics.

	Ligand	**AVI-1500**	**AVI-1501**	**AVI-3367**	**AVI-3765**	**AVI-3764**	**AVI-4051**	**AVI-3763**	**AVI-3762**	**AVI-4636**	**AVI-4206**
	PDB code	9CXY	9CXZ	7HC4	7HC5	7HC6	7HC7	7HC8	7HC9	7HCA	9CY0
	Beam line	ALS 8.3.1	ALS 8.3.1	ALS 8.3.1	ALS 8.3.1	ALS 8.3.1	ALS 8.3.1	SSRL 9-2	SSRL 9-2	ALS 8.3.1	ALS 8.3.1
	Wavelength (Å)	0.88557	0.88557	0.88557	0.88557	0.88557	0.88557	0.88557	0.88557	0.88557	0.77487
	Resolution range (Å)	39.9-1.03 (1.07-1.03)	44.5-1.02 (1.06 - 1.02)	39.7-1.00 (1.04 - 1.00)	44.4-0.98 (1.02-0.98)	44.5-1.03 (1.07-1.03)	39.7-0.99 (1.03-0.99)	39.7-1.01 (1.05-1.01)	39.7-1.05 (1.09-1.05)	44.47-1.03 (1.07-1.03)	33.7-0.80 (0.83-0.80)
	Space group	$P4_3$	$P4_3$	$P4_3$	$P4_3$	$P4_3$	$P4_3$	$P4_3$	$P4_3$	$P4_3$	P1
	Unit cell (α β γ, a b c)	88.8 88.8 39.5 90 90 90	88.9 88.9 39.4 90 90 90	88.8 88.8 39.5 90 90 90	88.8 88.8 39.5 90 90 90	88.8 88.8 39.6 90 90 90	88.8 88.8 39.4 90 90 90	88.8 88.8 39.6 90 90 90	88.8 88.8 39.6 9 0 90 90	88.9 88.9 39.3 90 90 90	30.3 39.8 64.4 89.9 77.8 90.1
	Total reflections	925861 (88714)	1019499 (92950)	1052667 (79477)	1095419 (68284)	981382 (94605)	1075242 (76799)	1049402 (101219)	934650 (89428)	996315 (94266)	420519 (10537)
	Unique reflections	151957 (14738)	156086 (15234)	165160 (15511)	175278 (16099)	152839 (14932)	169798 (16087)	161313 (15833)	142525 (13787)	151748 (14847)	235488 (6157)
	Multiplicity	6.1 (5.9)	6.5 (6.1)	6.4 (5.1)	6.2 (4.1)	6.4 (6.3)	6.3 (4.7)	6.5 (6.3)	6.6 (6.4)	6.6 (6.3)	1.8 (1.7)
	Completeness (%)	99.51 (96.98)	99.59 (97.52)	99.30 (93.65)	99.13 (91.70)	99.77 (98.28)	99.44 (94.83)	99.70 (98.49)	98.59 (96.15)	99.74 (98.30)	75.89 (19.87)
	Mean I/sigma(I)	13.96 (0.68)	15.02 (1.04)	13.32 (0.77)	11.98 (0.58)	9.03 (0.70)	12.87 (0.79)	12.16 (0.64)	10.78 (0.66)	13.86 (0.67)	13.15 (1.22)
	Wilson B-factor	13.38	12.91	12.4	12.14	11.92	12.15	11.98	12.53	14.12	6.69
	R-merge	0.0459 (2.25)	0.0439 (1.39)	0.0489 (1.38)	0.0546 (1.61)	0.0789 (1.73)	0.0521 (1.34)	0.0589 (2.38)	0.0672 (2.3)	0.0458 (2.24)	0.0334 (0.463)
	R-meas	0.0503 (2.47)	0.0477 (1.52)	0.0532 (1.54)	0.0594 (1.85)	0.0860 (1.88)	0.0567 (1.5)	0.0640 (2.60)	0.0730 (2.51)	0.0498 (2.44)	0.0472 (0.655)
	R-pim	0.0203 (0.995)	0.0184 (0.607)	0.0207 (0.665)	0.0233 (0.879)	0.0337 (0.751)	0.0222 (0.669)	0.0249 (1.03)	0.0282 (0.979)	0.0193 (0.961)	0.0334 (0.463)
	$CC_{1/2}$	0.999 (0.463)	0.999 (0.709)	0.999 (0.547)	0.999 (0.405)	0.998 (0.537)	0.999 (0.582)	0.999 (0.466)	0.999 (0.484)	0.999 (0.424)	0.997 (0.643)
	CC*	1 (0.795)	1 (0.911)	1 (0.841)	1 (0.759)	1 (0.836)	1 (0.858)	1 (0.797)	1 (0.808)	1 (0.772)	0.999 (0.885)
	Reflections used in refinement	151730 (14738)	156007 (15234)	164947 (15512)	174746 (16099)	152688 (14932)	169673 (16087)	161090 (15833)	142225 (13787)	151557 (14847)	235328 (6157)
	Reflections used for R-free	7357 (789)	7525 (740)	7958 (711)	8434 (781)	7391 (787)	8190 (751)	7762 (741)	6888 (690)	7340 (790)	11753 (303)
	R-work	0.1436 (0.4057)	0.1432 (0.3464)	0.1416 (0.4193)	0.1434 (0.4132)	0.1439 (0.4514)	0.1423 (0.3854)	0.1502 (0.4026)	0.1549 (0.5311)	0.1552 (0.3774)	0.1620 (0.2952)
	R-free	0.1609 (0.4006)	0.1594 (0.3372)	0.1583 (0.4254)	0.1587 (0.3953)	0.1595 (0.4464)	0.1580 (0.3611)	0.1686 (0.3973)	0.1773 (0.5333)	0.1735 (0.3805)	0.1884 (0.2959)
	CC(work)	0.977 (0.759)	0.975 (0.874)	0.975 (0.807)	0.975 (0.741)	0.975 (0.823)	0.974 (0.825)	0.973 (0.785)	0.974 (0.716)	0.972 (0.737)	0.954 (0.799)
	CC(free)	0.971 (0.779)	0.974 (0.881)	0.967 (0.823)	0.965 (0.777)	0.966 (0.750)	0.969 (0.847)	0.963 (0.779)	0.964 (0.677)	0.964 (0.753)	0.933 (0.763)
Number of atoms	Number of non-hydrogen atoms	3082	3046	3759	3756	3658	3675	3488	3811	4148	6135
	macromolecules	2609	2615	3260	3253	3162	3177	2992	3315	3644	5240
	ligands	35	31	45	37	37	47	43	43	39	204
	solvent	446	406	472	480	473	470	469	469	481	783
	Protein residues	338	338	337	336	336	336	336	337	337	336
RMS	Bonds (Å)	0.175	0.144	0.038	0.006	0.006	0.006	0.006	0.11	0.056	0.317
	Angles) (°)	3.98	3.8	1.3	0.98	0.96	0.95	0.98	2.27	1.71	5.69
Ramach-andran	Favored (%)	99.1	98.8	99.4	99.4	99.4	99.4	99.4	99.4	99.1	98.8
	Allowed (%)	0.9	1.2	0.6	0.6	0.6	0.6	0.6	0.6	0.9	1.2
	Outliers (%)	0	0	0	0	0	0	0	0	0	0
	Rotamer outliers (%)	0	0	2.54	1.12	0.87	0.86	1.81	1.39	0.76	0.69
	Clashscore	0.76	1.51	2.13	2.28	2.03	2.65	2.15	4.49	2.85	3.11
B-factor ($Å^2$)	Average	21.5	20.92	19.02	18.79	18.04	19.08	19.44	19.55	22.95	9.88
	Macromolecules	19.43	19.14	17.11	16.99	16.18	17.19	17.55	17.73	20.99	8.95
	Ligands	18.01	16.17	17.48	12.72	13.56	17.7	17.35	18.26	17.1	6.82
	Solvent	33.82	32.71	32.34	31.27	30.7	31.88	31.62	32.52	38.09	16.58

022 **Supplementary Table2** - Eurofins scanEDGE kinase assay shows no inhibition greater than >35% at 10
023 μM across a panel of diverse kinases
024

Compound Name	Entrez Gene Symbol	Percent Control
AVI-4206	ABL1	74
AVI-4206	ABL1	95
AVI-4206	ABL1	67
AVI-4206	ABL1	78
AVI-4206	ACVR1B	91
AVI-4206	CABC1	100
AVI-4206	AKT1	80
AVI-4206	AKT2	100
AVI-4206	ALK	69
AVI-4206	AURKA	95
AVI-4206	AURKB	77
AVI-4206	AXL	84
AVI-4206	BMPR2	92
AVI-4206	BRAF	70
AVI-4206	BRAF	99
AVI-4206	BTK	100
AVI-4206	CDK19	99
AVI-4206	CDK2	86
AVI-4206	CDK3	100
AVI-4206	CDK7	99
AVI-4206	CDK9	100
AVI-4206	CHEK1	90

AVI-4206	CSF1R	84
AVI-4206	CSNK1D	88
AVI-4206	CSNK1G2	97
AVI-4206	DCLK1	91
AVI-4206	DYRK1B	99
AVI-4206	EGFR	91
AVI-4206	EGFR	95
AVI-4206	EPHA2	100
AVI-4206	ERBB2	91
AVI-4206	ERBB4	100
AVI-4206	MAPK3	98
AVI-4206	PTK2	89
AVI-4206	FGFR2	100
AVI-4206	FGFR3	97
AVI-4206	FLT3	97
AVI-4206	GSK3B	81
AVI-4206	IGF1R	100
AVI-4206	CHUK	82
AVI-4206	IKBKB	93
AVI-4206	INSR	68
AVI-4206	JAK2	94
AVI-4206	JAK3	93
AVI-4206	MAPK8	88
AVI-4206	MAPK9	73

AVI-4206	MAPK10	88
AVI-4206	KIT	100
AVI-4206	KIT	100
AVI-4206	KIT	89
AVI-4206	STK11	39
AVI-4206	MAP3K4	96
AVI-4206	MAPKAPK2	85
AVI-4206	MARK3	94
AVI-4206	MAP2K1	55
AVI-4206	MAP2K2	60
AVI-4206	MET	98
AVI-4206	MKNK1	68
AVI-4206	MKNK2	70
AVI-4206	MAP3K9	100
AVI-4206	MAPK14	99
AVI-4206	MAPK11	91
AVI-4206	PAK1	100
AVI-4206	PAK2	88
AVI-4206	PAK4	100
AVI-4206	CDK16	83
AVI-4206	PDGFRA	41
AVI-4206	PDGFRB	91
AVI-4206	PDPK1	85
AVI-4206	PIK3C2B	100

AVI-4206	PIK3CA	100
AVI-4206	PIK3CG	100
AVI-4206	PIM1	100
AVI-4206	PIM2	86
AVI-4206	PIM3	100
AVI-4206	PRKACA	84
AVI-4206	PLK1	86
AVI-4206	PLK3	90
AVI-4206	PLK4	91
AVI-4206	PRKCE	76
AVI-4206	RAF1	95
AVI-4206	RET	100
AVI-4206	RIOK2	61
AVI-4206	ROCK2	74
AVI-4206	RPS6KA3	67
AVI-4206	NUAK2	68
AVI-4206	SRC	82
AVI-4206	SRPK3	92
AVI-4206	TGFBR1	84
AVI-4206	TEK	100
AVI-4206	NTRK1	99
AVI-4206	TSSK1B	100
AVI-4206	TYK2	100
AVI-4206	ULK2	100

AVI-4206	KDR	45
AVI-4206	STK32C	85
AVI-4206	ZAP70	91

Supplementary Table3 Pharmacokinetic parameters for AVI-4206 following IV (10 mg/kg), PO (50 mg/kg), and IP (100 mg/kg) doses in male CD1 mice (n = 3 per group).

IV (10 mg/kg)			PO (50 mg/kg)			IP (100 mg/kg)		
parameter	units	value	parameter	units	value	parameter	units	value
CL	ml/min/kg	69.5	T_{max}	hr	1.0	T_{max}	hr	0.250
V_{ss}	l/kg	1.32	C_{max}	ng/ml	94.0	C_{max}	ng/ml	38067
$T_{1/2}$	hr	0.833	$T_{1/2}$	hr	4.69	$T_{1/2}$	hr	3.17
AUC_{last}	hr*ng/ml	2396	AUC_{last}	hr*ng/ml	433	AUC_{last}	hr*ng/ml	40998
AUC_{INF}	hr*ng/ml	2399	AUC_{INF}	hr*ng/ml	442	AUC_{INF}	hr*ng/ml	41003
MRT_{INF}	hr	0.316	F	%	3.69	F	%	171

Liver blood flow (mouse) = 120 ml/min/kg.

Supplementary Table4 - ADMET panel shows no antagonist response greater than >15% at 10 μM.

Assay	Ligand or Substrate	Antagonist Response at 10 µM
Cholinesterase, Acetyl, ACES	Acetylthiocholine	4.1
Peptidase Bleomycin Hydrolase (BLMH)	Met-AMC	-0.4
Peptidase, CAN1 (CANPL1, Calpain-1)	Casein-FITC	5
Peptidase, CTSB (Cathepsin B)	Boc-Leu-Arg-Arg-AMC	-17.5
Peptidase, CTSG (Cathepsin G)	Suc-Ala-Ala-Pro-Phe-AMC	-3.2
Peptidase, CTSH (Cathepsin H)	L-Arg-AMC	-13.7
Peptidase, CTSK (Cathepsin K)	Z-Phe-Arg-AMC	-5
Peptidase, CTSL (Cathepsin L)	Z-Phe-Arg-AMC	2.6
Peptidase, CTSS (Cathepsin S)	Z-Leu-Arg-AMC	-50.7
Peptidase, CTSL2 (Cathepsin L2)	Z-Leu-Arg-AMC	-1.2
Peptidase, CTSZ (Cathepsin Z)	Mca-Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)-OH	-7.1
Peptidase, Chymase	Suc-Ala-Ala-Pro-Phe-AMC	-5.1
Peptidase, Chymotrypsin	Suc-Ala-Ala-Pro-Phe-AMC	-0.7
Peptidase, Factor VIIa	N-CH3-SO2-D-Phe-Gly-Arg-pNA	-3.3
Peptidase Kallikrein Plasma	Z-FR-AMC	7.9
Peptidase, PLAU (Urokinase)	Z-Gly-Gly-Arg-AMC	11.2
Cyclooxygenase COX-1	Arachidonic acid	0.6
Cyclooxygenase COX-2	Arachidonic Acid	5.7
Monoamine Oxidase MAO-A	Kynuramine	3.3
Phosphodiesterase PDE3A	FAM-cAMP	0.6
Phosphodiesterase PDE4D2	FAM-cAMP	0.8
Peptidase, CASP2 (Caspase 2)	Z-VDVAD-AFC	4.1
Peptidase, CASP4 (Caspase 4)	Ac-LEVD-AFC	-2.9

Peptidase, CASP5 (Caspase 5)	Ac-WEHD-AFC	-6.6
Peptidase, Prolyl Oligopeptidase (POP)	Z-Gly-Pro-AMC	-0.5
Peptidase, Plasmin	H-D-Val-Leu-Lys-pNA	-1.5
Peptidase, Thrombin	Z-Gly-Pro-Arg-AMC	0.4
Peptidase, Tissue Plasminogen Activator (tPA)	N-alpha-Z-D-Arg-Gly-Arg-pNA	1.5
Peptidase, Trypsin	Z-Gly-Pro-Arg-AMC	-1.6
Peptidase, Tryptase	Z-Gly-Pro-Arg-AMC	-0.5
Peptidase, ELA2 (Neutrophil Elastase 2)	N-MeOSuc-Ala-Ala-Pro-Val-pNA	-3
Peptidase, ELA1 (Pancreatic Elastase 1)	N-MeOSuc-Ala-Ala-Pro-Val-pNA	-2.2
Protein Tyrosine Kinase, LCK	Poly(Glu:Tyr)	-1.4
Peptidase, Dipeptidyl Peptidase 4 (DPP4, DPP IV)	GP-AMC	1.3
Peptidase, CASP1 (Caspase 1)	Z-YUAD-AFC	-0.9
Adenosine A2A	[3H]CGS-21680	-1
Adrenergic alpha1A	[3H]Prazosin	2.1
Adrenergic alpha2A	[3H]Rauwolscine	4.9
Adrenergic beta1	[125I]Cyanopindolol	2.4
Adrenergic beta2	[3H]CGP-12177	-10.5
Transporter, Norepinephrine (NET)	[125I]RTI-55	-2.4
Androgen (Testosterone)	[3H]Methyltrienolone	-1.5
Calcium Channel L-Type, Dihydropyridine	[3H]Nitrendipine	-6.2
Cannabinoid CB1	[3H]SR141716A	4.2
Cannabinoid CB2	[3H]WIN-55,212-2	6.7
Cholecystokinin CCK1 (CCKA)	[125I]CCK-8	-6.9
Dopamine D1	[3H]SCH-23390	-12.1

Dopamine D2S	[3H]Spiperone	-15.8
Transporter, Dopamine (DAT)	[125I]RTI-55	6
Endothelin ETA	[125I]Endothelin-1	3
GABAA, Flunitrazepam, Central	[3H]Flunitrazepam	-9.9
Glucocorticoid	[3H]Dexamethasone	6.9
Glutamate, NMDA, Agonism	[3H]CGP-39653	-2.9
Histamine H1	[3H]Pyrilamine	-12.8
Histamine H2	[125I]Aminopotentidine	2.5
Muscarinic M1	[3H]N-Methylscopolamine	-8.1
Muscarinic M2	[3H]N-Methylscopolamine	-0.4
Muscarinic M3	[3H]N-Methylscopolamine	-2.6
Opiate delta1 (OP1, DOP)	[3H]Naltrindole	-3.2
Opiate kappa (OP2, KOP)	[3H]Diprenorphine	6.3
Opiate mu (OP3, MOP)	[3H]Diprenorphine	8.2
Potassium Channel [KA]	[125I]alpha-Dendrotoxin	5.6
Potassium Channel hERG, [3H]Dofetilide	[3H]Dofetilide	-4.7
Serotonin (5-Hydroxytryptamine) 5-HT1A	[3H]8-OH-DPAT	-2.3
Serotonin (5-Hydroxytryptamine) 5-HT1B	[3H]GR125743	2.2
Serotonin (5-Hydroxytryptamine) 5-HT2A	[3H]Ketanserin	8.3
Serotonin (5-Hydroxytryptamine) 5-HT2B	[3H]Lysergic acid diethylamide (LSD)	-4.5
Serotonin (5-Hydroxytryptamine) 5-HT3	[3H]GR-65630	-3.2
Transporter, Serotonin (5-Hydroxytryptamine) (SERT)	[3H]Paroxetine	-2.2
Sodium Channel Nav1.5	[3H]BNZA	0.3
Vasopressin V1A	[125I]PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr	2

Nicotinic Acetylcholine alpha4beta2, Cytisine	[3H]Cytisine	4.7

Supplementary Table5 Macrodomain protein sequences

Protein	Use	Sequence
hMacroD2	HTRF	M**HHHHHH**SSGVDLGTENLYFQSYPSNKKKKVWREEKERLL KMTLEERRKEYLRDYIPLNSILSWKEEMKGKGQNDEENTQE TSQVKKSLTEKVSLYRGDITLLEVDAIVNAANASLLGGGGVD GCIHRAAGPCLLAECRNLNGCDTGHAKITCGYDLPAKYVIHT VGPIARGHINGSHKEDLANCYKSSLKLVKENNIRSVAFPCIST GIYGFPNEPAAVIALNTIKEWLAKNHHEVDRIIFCVFLEVDFKI YKKKMNEFFSVDDNNEEEEDVEMKEDSDENGPEEKQSVEE MEEQSQDADGVNTVTVPGPASEEAVEDCKDEDFAKDENIT KGGEVTDHSVRDQDHPDGQENDSTKNEIKIETESQSSYMET EELSSNQEDAVIVEQPEVIPLTEDQEEKEGEKAPGEDTPRM PGKSEGSSDLENTPGPDAGAQDEAKEQRNGTKGLNDIFEA QKIEWHE
Targ1	HTRF	M**HHHHHH**SSGVDLGTENLYFQSMASSLNEDPEGSRITYVK GDLFACPKTDSLAHCISEDCRMGAGIAVLFKKKFGGVQELL NQQKKSGEVAVLKRDGRYIYYLITKKRASHKPTYENLQKSLE AMKSHCLKNGVTDLSMPRIGCGLDRLQWENVSAMIEEVFE ATDIKITVYTL
Mac1	HTRF	MSYY**HHHHHH**LESTSLYKKAGFLEVLFQGPEVNSFSGYLKL TDNVYIKNADIVEEAKKVKPTVVVNAANVYLKHGGGVAGAL NKATNNAMQVESDDYIATNGPLKVGGSCVLSGHNLAKHCL HVVGPNVNKGEDIQLLKSAYENFNQHEVLLAPLLSAGIFGAD PIHSLRVCVDTVRTNVYLAVFDKNLYDKLVSSFLEMKSEK
Mac1	CETS A	MDYKDHDGDYKDHDIDYKDDDDKGGGSGGGSGGGSTIEV NSFSGYLKLTDNVYIKNADIVEEAKKVKPTVVVNAANVYLKH GGGVAGALNKATNNAMQVESDDYIATNGPLKVGGSCVLSG HNLAKHCLHVVGPNVNKGEDIQLLKSAYENFNQHEVLLAPL LSAGIFGADPIHSLRVCVDTVRTNVYLAVFDKNLYDKLVSSF LEMKGSVSGWRLFKKISGSEGRGSLLTCGDVEENPGPMVS ELIKENMHMKLYMEGTVNNHHFKCTSEGEGKPYEGTQTMRI KAVEGGPLPFAFDILATSFMYGSKTFINHTQGIPDFFKQSFP EGFTWERVTTYEDGGVLTATQDTSLQDGCLIYNVKIRGVNF PSNGPVMQKKTLGWEASTETLYPADGGLEGRADMALKLVG GGHLICNLKTTYRSKKPAKNLKMPGVYYVDRRLERIKEADK ETYVEQHEVAVARYCDLPSKLGHR*



Supplementary Figure1 - X-ray density for ligand modeling. Ligands were modeled using either traditional F_O-F_C electron density maps (AVI-1500, AVI-1501, AVI-4206) or PanDDA event maps (AVI-4051, AVI-3367, AVI-3763, AVI-3762, AVI-3765, AVI-3764 and AVI-4636). The diffraction resolution and refined occupancy are indicated for each ligand. The occupancy is indicated for each confirmation when multiple ligand poses were modeled.

038



Supplementary Figure2. AVI-4206 and AVI-219 inhibition of Mac1 determined using auto-mono-ADP-ribosylated PARP10 as a substrate.
(A) Standard curve of ADP-ribose detected using 100 nM NUDT5 and the AMP-Glo assay kit. Data are presented mean ± SD for four technical replicates. Data were fitted with a power function in the form $y = kx^a$ using non-linear regression (gray line).
(B) Titration of Mac1 with auto-mono-ADP-ribosylated PARP10. The concentration of PARP10 was 10 μM based on absorbance at 280 nm, but the titration indicated that the concentration of ADP-ribose released by Mac1 was five-fold lower (~2 μM). Data are presented mean ± SD for four technical replicates.
(C) Counterscreen of compounds against 100 nM NudT5 with 2 μM ADP-ribose as a substrate. No inhibition was detected up to 1 mM compound. Data are presented mean ± SD for four technical replicates.



Supplementary Figure3: AVI-4206 increases thermal stability of Mac1 in cells.
(A) CETSA-WB shows thermal stabilization of FLAG-tagged Mac1 protein after treatment of A549 cells with 10 μM of AVI-4206.
(B) Densitometry values were normalized to the lowest temperature for each treatment. Data are presented as a single densitometry measurement.



Supplementary Figure4: **Thermal proteome profiling in A549 cellular lysates.**
(A) Melting curve for Mac1 in A549 lysates treated in duplicate with either DMSO or 100 μM of AVI-4206. Data were normalized to the mean intensity at 37°C. Data were fitted with a sigmoidal dose-response equation using non-linear regression (gray line).
(B) Volcano plot of the statistical significance and degree of melting temperature shift for all proteins with high quality melting curves (n= 3,446 proteins). Teal circles indicate proteins with a statistically significant shift in melting temperature (adjusted *P* value < 0.05). The highest non-significant proteins are labeled and do not have obvious functional overlap with macrodomains.

042



Supplementary Figure5: AVI-4206 has limited antiviral efficacy and no cytotoxicity in cellular models of infection.

(A and B) Drug cytotoxicity of AVI-4206 in Vero-TMPRSS2 (A) and A549 ACE2^h (B) was measured using the CellTiter-Glo® viability assay. Graphs represent the mean ± SD of three biological replicates each conducted in triplicate.

(C and D) Luciferase readout of VAT (C) and A549 ACE2^h (D) cells infected with WA1 or WA1 Mac1 N40D replicons and treated with or without AVI-4206 and IFN-ɣ at indicated concentrations. Results are plotted as normalized mean ± SD luciferase values of a representative biological experiment containing three technical replicates.

043
044
045
046
047



Supplementary Figure6: **Lower dose AVI-4206 reduces viral replication and increases survival *in vivo***.
(A) K18-hACE2 mice were intranasally infected SARS-CoV-2 WA1 or SARS-CoV-2 WA1 Mac1 N40D mutant. Mice were treated as indicated with AVI-4206 (BID, 30 mg/kg) or vehicle. Each group was composed of n=10 mice (5 mice per time point).
(B) The percent body weight loss is presented as mean ± SD. **, $P < 0.01$; ***, $P < 0.001$ by two-tailed Student's t-test relative to the vehicle control at each timepoint.

(C) Survival curve based on the percent body weight loss humane endpoint.
(D) Viral load in the lung at indicated time points is presented as mean ± s.e.m. **, $P < 0.01$ by Mann Whitney's test relative to the vehicle control.

048